| Excerpt | Reference |
|---|
| "Treatment of advanced Hodgkin's disease by associating vincristine, adriblastine, prednisone and procarbazine is compared with other widely employed protocols." | ( Buttolo, Q; Colle, R; Maiolini, E; Marinone, G; Mauro, PL, 1975) |
| "Progress in the chemotherapy of Hodgkin's disease and experimental therapeutic, pharmacologic, and clinical studies of the antitumor antibiotic, adriamycin, are presented in this abstract." | ( Frei, E, 1975) |
| "In 18 patients with advanced Hodgkin's disease, refractory to previous 'C-MOPP' treatment, a new therapeutic protocol of adriamycin, DTIC, CCNU and bleomycin was introduced." | ( Bruntsch, U; Gallmeier, WM; Osieka, R; Schmidt, CG; Seeber, S, 1976) |
| "117 patients with stage IIIA Hodgkin's disease were randomly allocated for treatment in a multicentre trial comparing the results of total nodal irradiation (T." | ( , 1976) |
| "Thirty-seven patients with advanced Hodgkin's disease have been treated for greater than or equal to 3 months with a protocol consisting of alternate monthly courses of MOPP (mechlorethamine, Oncovin [vincristine], procarbazine, and prednisone) and ABDV (adriamycin, bleomycin, DTIC, and vinblastine) with local radiotherapy (RT) to areas of originally bulky disease." | ( Case, DC; Clarkson, BD; Lee, BJ; Nisce, L; Young, CW, 1976) |
| "Twenty-four patients with advanced Hodgkin's disease, resistant to the MOPP regimen, were treated with a combination of Adriamycin, bleomycin, dacarbazine and vinblastine (ABDV)." | ( Case, DC; Lee, BJ; Young, CW, 1977) |
| "A 40 year old woman with Hodgkin's disease twice developed signs of encephalitis while being treated with prednisone and cyclophosphamide for 10 months." | ( Amare, M; Frenkel, JK; Larsen, W, 1978) |
| "Among 106 patients with Hodgkin's lymphoma in stage IIIB and IVB treated from September 1969 to June 1977 by a working team for hematology and oncology at the clinic and outpatients clinic of the Medical School of Erfurt, there were two cases (=1." | ( Fink, R; Trux, F; Wutke, K, 1978) |
| "Twenty-one patients with advanced Hodgkin's disease resistant to MOPP (mechlorethamine, vincristine, procarbazine, prednisone) were treated with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)." | ( Bonadonna, G; Santoro, A, 1979) |
| "Patients with Hodgkin's disease, malignant melanoma and breast cancer responded to this combination chemotherapy." | ( Kolarić, K, 1977) |
| "Optimal treatment in Hodgkin's disease requires the knowledge of the stage the disease has reached." | ( Huhn, D; Wilmanns, W, 1979) |
| "Cellular immunity in 64 patients with Hodgkin's disease was studied during diagnosis before any treatment." | ( Goasguen, J; Guerin, D; Le Prise, PY; Leblay, R; Richier, JL, 1977) |
| "Three cases are described, 2 of Hodgkin's disease and a further case of bronchial carcinoma, where high dosage ascorbic acid treatment appeared to be associated with the development of potentially dangerous symptoms." | ( Campbell, A; Jack, T, 1979) |
| "The patient had Hodgkin's disease and responded to chemotherapy and amphotericin B." | ( Dwyer, R; Piken, E; Zablen, MA, 1978) |
| "Thirty-four children with Hodgkin's disease were treated during the years 1969--75." | ( Armata, J; Borkowski, W; Depowska, T; Depowski, M; Kaczor, Z; Stopyrowa, J; Strzeszynski, J, 1978) |
| "In patients with Hodgkin's disease resistant to MOPP treatment and requiring additional cytotoxic drugs, combination chemotherapy including DTIC may induce remissions in more than half of these patients." | ( Grünewald, K; Huber, H, 1978) |
| "Seventy-four patients with Hodgkin's disease and 31 patients with non-Hodgkin's lymphoma were studied from 3 to 186 months after cessation of therapy for lymphoma." | ( Eyre, HJ; Grozea, PC; King, GW; LoBuglio, AF, 1979) |
| "No deaths from Hodgkin's disease have occurred in patients who received combined modality therapy, whereas 24 per cent of the patients who received radiotherapy alone have died with active disease." | ( Diggs, C; Gustafson, J; Schimpff, SC; Wiernik, PH, 1979) |
| "Of 14 splenectomized patients with Hodgkin's disease who were treated with total nodal irradiation and combination chemotherapy (MOPP), fulminant sepsis developed in three (21." | ( Aisenberg, AC; Weitzman, S, 1977) |
| "The ideal management of stage IIB Hodgkin's disease is less certain; it is our plan to study the efficacy of combined modality treatment." | ( Goldstein, M; Goodman, R; Hellman, S; Mauch, P; Piro, A; Rosenthal, D; Tullis, J, 1977) |
| "Thirty-two patients with Hodgkin's disease who relapsed after a first complete remission induced by nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) were retreated with MOPP chemotherapy." | ( DeVita, VT; Fisher, RI; Hubbard, SP; Simon, R; Young, RC, 1979) |
| "In 3 years, 118 patients with Hodgkin's disease have completed chemotherapy with chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP)." | ( Austin, DE; Barrett, A; Juttner, CA; Kaye, SB; McElwain, TJ; Peckham, MJ; Smith, IE, 1979) |
| "Of 18 patients with advanced Hodgkin's disease who obtained a complete remission with a modified De Vita treatment protocol 15 maintained their complete remission for an average of 76 months till the end of the observation time." | ( Hiller, E; Wilmanns, W; Wilms, K, 1979) |
| "A 26-year-old woman with Hodgkin's disease was treated with multiple-agent chemotherapy at 26 weeks' gestation." | ( Jones, RT; Weinerman, BH, 1979) |
| "Ten patients with advanced Hodgkin's disease refractory to combination therapy with nitrogen mustard, vincristine sulfate, procarbazine, and prednisone (MOPP) were treated with a combination of doxorubicin hydrochloride and lomustine." | ( Einhorn, LH; Williams, SD, 1977) |
| "A patient with Hodgkin's disease and renal insufficiency became deaf while being treated with high dose oral furosemide." | ( de Quesada, AM; Pickering, MJ; Rifkin, SI; Shires, DL, 1978) |
| "Despite the dramatic response of Hodgkin's disease to intensive chemotherapy, the skin lesion was rapidly transformed into squamous cell carcinoma in 10 weeks." | ( Poleksic, S; Yeung, KY, 1978) |
| "After 12 cycles of MOPP therapy for Hodgkin's Disease, an adolescent black male developed hemorrhagic cystitis, which clinically and histologically was similar to that induced by cyclophosphamide." | ( Royal, JE; Seeler, RA, 1978) |
| "We studied 19 Ugandan boys with Hodgkin's disease who had been treated with mechlorethamine, vincristine, procarbazine and prednisone and who survived at least two years to assess testicular germ-cell depletion in pubescent boys on combination chemotherapy, as had previously been demonstrated in sexually mature men." | ( Olweny, CL; Sherins, RJ; Ziegler, JL, 1978) |
| "Between 1967 and 1977, 48 patients with Hodgkin's disease under 16-years-old were treated with MOPP chemotherapy alone at the Uganda Cancer Institute because radiotherapy facilities are not available." | ( Katongole-Mbidde, E; Kiire, C; Lwanga, SK; Magrath, I; Olweny, CL; Ziegler, JL, 1978) |
| "11 pretreated patients with advanced Hodgkin's disease were treated according to the ABVD schedule." | ( Baumgartner, G; Höcker, P; Lutz, D; Waldner, R, 1978) |
| "Two patients with Hodgkin's disease are described who were treated with nitrogen mustard, vincristine, procarbazine, and prednisone and developed diffuse lung disease." | ( Armstrong, JD; Farney, RJ; Hammer, S; Morris, AH, 1977) |
| "Fifty patients with advanced Hodgkin's disease were treated with a combination of cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) in a 21-day cyclic regimen." | ( Diggs, CH; Kvols, LK; Levi, JA; Wiernik, PH, 1977) |
| "Study 81 cases of Hodgkin's disease at stages I, II or III led to the following conclusions from a therapeutic standpoint (in relation to the apparent results obtained): The addition of chemotherapy on the form of three courses of MOPP before irradiation improved the results of the latter on the one hand and, principally, by reducing the number of failures and, secondly, by reducing the complications." | ( Baillet, F; Brun, B; Dreyfus, B; Maylin, C; Mazeron, JJ; Pierquin, B, 1977) |
| "Seventy patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (Ch1VPP)." | ( Austin, DE; McElwain, TJ; Peckham, MJ; Smith, E; Toy, J, 1977) |
| "We studied 680 patients with Hodgkin's disease, treated at Stanford University Medical Center from July 1, 1968, through December 31, 1975, to determine the risk of development of hematologic neoplasia." | ( Coleman, CN; Flint, A; Glatstein, EJ; Kaplan, HS; Rosenberg, SA; Williams, CJ, 1977) |
| "The treatment of a case of Hodgkin's disease (lymphocyte predominance, stage IV B) with exogenous i." | ( Blomgren, H; Cantell, K; Johansson, B; Lagergren, C; Ringborg, U; Strander, H, 1976) |
| "Thirty-eight patients with advanced Hodgkin's disease were treated with a combination of cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP)." | ( Bloomfield, CD; Fortuny, I; Kennedy, BJ; Vosika, G; Weiss, RB, 1976) |
| "A new treatment program for advanced Hodgkin's disease employing five-drug combination chemotherapy and low dose radiation to the sites of bulk disease (nodal or parenchymal) was designed in 1969." | ( Bertino, JR; Farber, LR; Fischer, DB; Fischer, JJ; Prosnitz, LR, 1976) |
| "This is a report of a patient with Hodgkin's disease who underwent a staging splenectomy and extensive radiation therapy and then developed "idiopathic" thrombocytopenic purpura." | ( Julia, A; Miller, SP, 1976) |
| "Forty-five children with advanced Hodgkin's disease (stages III and IV) received combination chemotherapy in three schedules: MOPP (mustargen, Oncovin, procarbazine, prednisolone); COPP (cyclophosphamide was substituted for mustargen); and CVPP (cyclophosphamide, vinblastine, procarbazine, prednisone)." | ( Kolygin, BA, 1976) |
| "A case of nodular sclerosis Hodgkin's disease, stage IVB, with lung involvement and hypertrophic pulmonary osteoarthropathy (HPOA), was treated with quadruple cytotoxic chemotherapy." | ( Atkinson, MK; McElwain, TJ; Peckham, MJ; Thomas, PP, 1976) |
| "The case of a patient who developed Hodgkin's disease three years after commencement of therapy with phenytoin is presented." | ( Forbes, IJ; Sorrell, TC, 1975) |
| "Ten patients with Hodgkin's disease treated six months previously with levamisole were restudied." | ( Biniaminov, M; Ramot, B; Rosenthal, E; Shoham, C, 1976) |
| "204 patients with Hodgkin's disease not previously treated were given vincristine, chlormethine, procarbazine and prednisone (protocol H2-65) for six months, followed by monthly vinblastine injections." | ( Auclerc, G; Bernard, J; Boiron, M; Chastang, CL; Chelloul, N; Delbrück, H; Jacquillat, CL; Weil, M, 1975) |
| "The results of modern radiotherapy for Hodgkin's disease are correlated to the stage of the disease." | ( Rosenberg, SA, 1975) |
| "Seventeen patients with Hodgkin's disease and 15 with non-Hodgkin's lymphoma were subjected to nontherapeutic splenectomy as part of the staging procedure prior to their initial treatment with MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) or CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy, respectively." | ( Canellos, GP; DeVita, VT; Ihde, DC; Young, RC, 1976) |
| "A 27 year old man with Hodgkin's disease experienced three separate episodes of chest pain, each occurring on the sixth day of a cycle of mustargen, oncovin, procarbazine, prednisone (MOPP) combination chermotherapy." | ( Greenwald, ES; Grossman, J; Weinstein, P, 1976) |
| "Most patients with Hodgkin's disease had received intensive radiation therapy." | ( Rosner, F, 1976) |
| "Four patients with fresh Hodgkin's disease were treated with MOPP/ABV hybrid regimen using nitrogen mustard-N-oxide hydrochloride (NH2-O)." | ( Kodo, H; Kozai, Y; Ohyama, T; Tomori, G, 1992) |
| "Fourteen patients with relapsed Hodgkin's disease responded to a salvage therapy with Dexa-BEAM (dexamethasone, BCNU, etoposide, Ara-C and melphalan)." | ( Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B, 1992) |
| "65 adult patients with Hodgkin's disease were treated acc." | ( Filip, A; Gabryś, K; Kotlarek-Haus, S; Kuliszkiewicz-Janus, M; Wołowiec, D, 1992) |
| "20 untreated Hodgkin's disease patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given doxorubicin, bleomycin, etoposide and prednisone on a 21-day cycle." | ( Alberto, P; Mermillod, B; Zulian, GB, 1992) |
| "2846 patients first treated for Hodgkin's disease during 1970-87, for whom follow up was complete in 99." | ( Bennett, MH; Douglas, AJ; Hudson, BV; Hudson, GV; MacLennan, KA; Swerdlow, AJ, 1992) |
| "Group two included Hodgkin's disease patients who were treated 12-24 years previously and have been continuously free of disease." | ( Brown, JM; Evans, JW; Mori, M; Smith, LM, 1992) |
| "In three patients with advanced Hodgkin's disease treated with combination chemotherapy (MOPP) incorporating vincristine, and receiving at the same time a fixed daily dose of 8000 U of rHu-EPO subcutaneously for 10 to 15 days because of myelosuppressive anemia, myeloaspirates were performed one week before and 24 hours after the administration of vincristine." | ( Marmont, AM, 1992) |
| "Modern treatment plans for early staged Hodgkin's disease must focus on optimal disease-free survival results without laparotomy, minimal acute toxicity, and reduced long-term complications." | ( Cabanillas, F; Fuller, L; Hagemeister, FB; McLaughlin, P; Rodriguez, M; Romaguera, J; Swan, F, 1992) |
| "Responses of the Hodgkin's disease to this therapy were favourable but short-lived." | ( Baglin, TP; Flavell, DJ; Flavell, SU; Lim, SH; Marcus, RE; Wimperis, JZ, 1992) |
| "The cases of 63 children treated for Hodgkin's disease were retrospectively evaluated according to clinical and laboratory characteristics at initial appearance, clinical and pathologic staging, and treatment for their effects on survival and disease-free survival." | ( Aeppli, D; Day, DL; Heise, R; Lee, CK; McClain, KL; Woods, WG, 1990) |
| "Blood leukocyte DNA obtained from 11 Hodgkin's disease patients undergoing ABVD chemotherapy was analysed for the presence of the precarcinogenic adduct O6-methylguanine (O6-meG) at various times (1-2 h up to 49 h) after i." | ( Boussiotis, VA; Kyrtopoulos, SA; Pangalis, GA; Souliotis, VL, 1991) |
| "Forty-nine patients with Hodgkin's disease who relapsed after a first complete remission of more than 12 months following primary chemotherapy were treated with salvage therapy regimens." | ( Bonadonna, G; Bonfante, V; Negretti, E; Santoro, A; Valagussa, P; Viviani, S, 1990) |
| "Reports on salvage treatments for Hodgkin's disease in first relapse after primary chemotherapy should include data on the proportion of patients having stage IV disease at diagnosis, B symptoms at relapse, and a time from primary treatment to relapse of less than 1 year." | ( Barnett, M; Connors, JM; Fairey, RN; Lohri, A; O'Reilly, SE; Phillips, GL; Reece, D; Voss, N, 1991) |
| "47 patients with stages IIIB and IV Hodgkin's disease underwent laparotomy with splenectomy as restaging procedure after first-line chemotherapy (CT) which included 4 cycles of CT ABV/IMEP/PCAV/ABV." | ( Bourstyn, E; Brice, P; Colin, P; D'Agay, MF; Extra, JM; Fermand, JP; Fermé, C; Frija, J; Lepage, E; Miclea, JM, 1991) |
| "Sixty-two patients with advanced-stage Hodgkin's disease and a median age of 12 years (range, 3 to 22 years) were treated with four cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) alternating with four cycles of doxorubicin, vinblastine, bleomycin, and dacarbazine (ABVD) followed by low-dose radiotherapy (RT)." | ( Behm, FG; Brecher, M; Cantor, A; Chauvenet, A; Leventhal, BG; Marcus, R; Ternberg, J; Weiner, MA; Wharam, M, 1991) |
| "Treatment of disseminated Hodgkin's disease still fails in about 50 percent of the cases." | ( Bastion, Y; Coiffier, B; Tigaud, JD, 1991) |
| "Eighty patients with advanced Hodgkin's disease were randomized either to treatment with combination of doxorubicin, bleomycin, vinblastine, and prednisone (ABVP), alternating with lomustine, vincristine, procarbazine, and prednisone (LOPP)--Group A, or to combination of cyclophosphamide, vincristine, procarbazine, prednisone, and low dose of bleomycin (COPP-Bleo)--Group B." | ( Bohunický, L; Fuchsberger, P; Gyárfás, J; Koza, I; Mardiak, J; Mociková, K; Spánik, S; Sufliarsky, J; Svancárová, L; Thalmeinerová, Z, 1991) |
| "A case of Hodgkin's disease associated from the start with visceral leishmaniasis in the absence of antitumoral treatment shows that leishmaniasis is a severe opportunistic infection in endemic areas and can be masked by the tumoral syndrome of an underlying pathology." | ( Blanc, AP; Jacquème, P; Magnan, A; Poirier, R; Redding, E; Sudan, N, 1991) |
| "Thirty-three patients with advanced Hodgkin's disease were treated with a combination chemotherapy consisting of vincristine 1 mg/m2 iv on day 1, 8, cyclophosphamide 500 mg/m2 iv on day 1, procarbazine 100 mg/m2 p." | ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Itami, S; Kuraishi, Y; Mizunuma, N; Mukaiyama, T; Ogawa, M; Tabata, M, 1991) |
| "The patient remains free of Hodgkin's disease 34 months after completion of chemotherapy." | ( Connaghan, DG; Johnston, PG; Longo, DL; Ruscetti, FW; Sullivan, FJ, 1991) |
| "Twenty patients with relapsed Hodgkin's disease have been treated with a weekly regimen of chemotherapy (VAPEC-B) comprising Adriamycin 35 mg/m2 i." | ( Crowther, D; Radford, JA, 1991) |
| "Untreated patients with Hodgkin's disease (HD) have a blood T-lymphocytopenia mainly caused by a reduction of the CD4+ subset." | ( Björkholm, M; Grimfors, G; Holm, G; Mellstedt, H; Schnell, PO; Tullgren, O, 1990) |
| "The treatment of Hodgkin's disease after relapse from chemotherapy or when resistant to chemotherapy rarely results in cure." | ( Goldstone, A; McMillan, A, 1991) |
| "Fifty patients with advanced-stage Hodgkin's disease (HD) who relapsed or failed to respond to multiple regimens of combination chemotherapy were entered onto two autologous bone marrow transplantation (AuBMT) protocols." | ( Gulati, S; Yahalom, J, 1991) |
| "Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group." | ( Anderson, JR; Bierman, PJ; Dowling, MD; Howe, D; Hutchins, M; Moravec, DF; Okerbloom, J; Sorensen, S; Vose, JM; Weisenburger, D, 1991) |
| "Chemotherapy for Hodgkin's disease causes a high and apparently dose-related incidence of testicular dysfunction in prepubertal as well as in pubertal boys affecting Leydig cell function as well as spermatogenesis." | ( Brämswig, JH; Heiermann, E; Heimes, U; Nieschlag, E; Schellong, G; Schlegel, W, 1990) |
| "The progeny of patients treated for Hodgkin's disease appear normal and no excess fetal wastage has been noted." | ( Donaldson, SS; Ortin, TT; Shostak, CA, 1990) |
| "Patients with early-staged Hodgkin's disease have had a higher relapse rate following radiotherapy alone if they have B symptoms, large mediastinal masses, hilar involvement, or stage III disease." | ( Cabanillas, F; Hagemeister, FB; Liang, JC; McLaughlin, P; Meistrich, ML; Redman, JR; Rodríguez, MA; Romaguera, JE; Swan, F; Velásquez, WS, 1990) |
| "After the diagnosis of stage IIIS Hodgkin's disease, combined COPP chemotherapy was initiated." | ( Akyol, H; Akyüz, C; Büyükpamukçu, M; Sarialioğlu, F, 1990) |
| "We treated 58 patients (28 with non-Hodgkin's lymphoma [NHL], 30 with Hodgkin's disease [HD]) at seven dose levels of CBV." | ( Antin, JH; Ault, KA; Bubley, GJ; Churchill, WH; Come, SE; Rappaport, JM; Rosenthal, DS; Schnipper, LE; Smith, BR; Wheeler, C, 1990) |
| "A 9-year-old boy with Hodgkin's disease developed measles 1 month after completing eight courses of intensive anti-cancer chemotherapy." | ( Gururangan, S; Morris, DJ; Stevens, RF, 1990) |
| "A patient with advanced Hodgkin's disease being treated with MOPP chemotherapy presented with delayed life-threatening pulmonary toxicity secondary to procarbazine." | ( Alvarez, S; Ancalmo, N; Brooks, BJ; Grinton, SF; Hendler, NB, 1990) |
| "Many patients with advanced Hodgkin's disease continue to need palliative therapy, but where there is no curative intent, patients and doctors may prefer oral treatment only." | ( Carey, PJ; Jackson, GH; Lennard, AL; Proctor, SJ, 1990) |
| "Seventy patients with advanced Hodgkin's disease, 54 with new disease, and 16 in first relapse after initial radiotherapy, have been treated with a seven-drug, 8-month program: MOPP (nitrogen mustard, vincristine, procarbazine, prednisone)/ABV (Adriamycin [Adria Laboratories of Canada, Mississauga, Ontario], bleomycin, vinblastine) hybrid." | ( Connors, JM; Klimo, P, 1985) |
| "Eight patients with disseminated Hodgkin's disease resistant to MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) chemotherapy were treated with high-dose chemoradiotherapy and marrow transplantation from an HLA-identical sibling." | ( Appelbaum, FR; Buckner, CD; Clift, RA; Deeg, HJ; Neiman, PE; Sanders, JE; Stewart, P; Storb, R; Sullivan, KM; Thomas, ED, 1985) |
| "A 44-year-old man with Hodgkin's disease developed fever and erythematous macules and plaques associated with doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy." | ( Beutner, KR; Markowitch, W; Packman, CH, 1986) |
| "Most of the children with Hodgkin's disease diagnosed before or during puberty can be cured with chemotherapy alone, and thus will not suffer from the damaging late effects of radiotherapy." | ( Behrendt, H; Van Bunningen, BN; Van Leeuwen, EF, 1987) |
| "In 1982 a French cooperative study for Hodgkin's disease was designed to minimize adverse side effects of therapy in childhood." | ( Lemerle, J; Leverger, G; Oberlin, O; Schaison, G, 1987) |
| "Thirty eight patients with Hodgkin's disease, stage I to IIIA, previously untreated, received three courses of this regimen before radical radiotherapy." | ( Audebert, A; Blanc, CM; David, B; Debray, J; Eghbali, H; Hoerni, B; Rojouan, J; Zittoun, R, 1987) |
| "Thirty-two patients with advanced Hodgkin's lymphoma resistant to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) were treated with a salvage chemotherapy regimen consisting of lomustine, etoposide, vindesine, and dexamethasone (CEVD)." | ( Diehl, V; Fuchs, R; Loeffler, M; Pflüger, KH; Pfreundschuh, MG; Schoppe, WD, 1987) |
| "The observed cure rates in childhood Hodgkin's disease (85 to 95%) and the knowledge of late complications of treatments, radiotherapy as well as chemotherapy, lead to studies aiming at decreasing the treatment burden without compromising these good results." | ( Habrand, JL; Lemerle, J; Leverger, G; Oberlin, O; Olive, D; Schaison, G; Zucker, JM, 1988) |
| "Results of treatment of 25 Hodgkin's disease patients at Kyushu University Hospital from 1981 to 1985 were reviewed." | ( Hayabuchi, N; Hirata, H; Ishii, E; Jingu, K; Kikuchi, M; Komiyama, S; Masuda, K; Miyoshi, M; Nishimura, J; Shibuya, T, 1988) |
| "A nineteen year old female patient with Hodgkin's disease of the mixed type was treated with sequential radio- and chemotherapy according to the ABVD-regimen." | ( Herrmann, G; Hübner, K, 1988) |
| "Fifty patients with recurrent Hodgkin's disease have been treated with high-dose therapy followed by autologous bone marrow transplantation." | ( Carella, AM; Cimino, G; Congiu, AM; Coser, P; Gaozza, E; Mangoni, L; Mazza, P; Meloni, G; Ricci, P; Visani, G, 1988) |
| "Fifty patients with Hodgkin's disease stage I to IIIA, previously untreated, received three courses of this regimen before radiotherapy." | ( Blanc, CM; David, B; Eghbali, H; Hoerni, B; Orgerie, MB; Rojouan, J; Zittoun, R, 1988) |
| "Since pediatric Hodgkin's disease is a curable malignancy, it is essential to limit treatment sequelae." | ( Donaldson, SS; Link, MP; Mefferd, JM, 1989) |
| "As salvage therapy in non-Hodgkin's lymphoma (NHL), IMV-Bleo (ifosfamide, methotrexate, etoposide, bleomycin) produced a complete remission (CR) rate of 41% and seemed to be particularly effective in patients with suboptimal response to first-line treatment." | ( Diehl, V; Schaadt, M; von Kalle, AK, 1989) |
| "Untreated patients with Hodgkin's lymphoma in stages I-IIIA with risk factors (large mediastinal mass, massive splenic involvement, extranodal disease) were entered into the HD1 protocol and received a combined chemo-radiotherapy [2 X (COPP + ABVD) + 40 Gy extended field irradiation (EF) vs 2 X (COPP + ABVD) + 20 Gy EF]." | ( Diehl, V; Gerhartz, H; Hiller, E; Kirchner, H; Löffler, M; Petsch, S; Pfreundschuh, M; Rühl, U; Schoppe, W; Wilmanns, W, 1989) |
| "Eight patients with refractory Hodgkin's disease received intensive combination chemotherapy conditioning with cyclophosphamide, carmustine (BCNU), and etoposide (VP 16-213), and allogeneic marrow transplants." | ( Barnett, MJ; Connors, JM; Fay, JW; Herzig, GP; Herzig, RH; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD; Wolff, SN, 1989) |
| "Seventeen patients with advanced stage Hodgkin's disease who relapsed or failed to respond to multiple regimens of combination chemotherapy (mostly Mechlorethamine, Vincristine, Procarbarzine, Prednisone and Adriamycin, Bleomycin, Vinblastine, Dacarbazine) were treated with accelerated hyperfractionated total lymphoid irradiation (TLI) and high-dose chemotherapy followed by autologous bone marrow transplantation (AuBMT)." | ( Clarkson, B; Fuks, Z; Gulati, S; Shank, B; Yahalom, J, 1989) |
| "Thus, patients with early-stage Hodgkin's disease can be treated with radiation therapy with little to no risk of irreversible testicular injury." | ( Fraass, B; Glatstein, E; Kinsella, TJ; Miller, R; Rowland, J; Sherins, RJ; Sorace, R; Steinberg, SM; Trivette, G, 1989) |
| "Neoadjuvant chemotherapy in Hodgkin's disease has improved survival time and tolerance to irradiation, allowing a lowering of the total doses used and the volumes irradiated." | ( Alapetite, C; Baillet, F; Dessard-Diana, B; Housset, M; Jacquillat, C; Michel-Langlet, P, 1989) |
| "Forty patients with refractory Hodgkin's disease (24 patients) or non-Hodgkin's lymphoma (16 patients) who were considered for high-dose therapy but not for autologous bone marrow transplantation (ABMT) due to BM metastases, previous pelvic irradiation, a history of marrow involvement by tumor or hypocellular marrow in conventional harvest sites received high-dose therapy and autologous peripheral blood (PB) hematopoietic stem cell transplantation." | ( Armitage, JO; Bierman, PJ; Kessinger, A; Landmark, JD; Smith, DM; Weisenburger, DD, 1989) |
| "At Kanazawa University 28 patients with Hodgkin's disease were treated between 1975 and 1988." | ( Nakamura, S; Ohtake, S, 1989) |
| "Fifty-three patients with advanced Hodgkin's disease, most of them previously treated, received 8 to 16 courses of modified MOPP regimens (nitrogen mustard replaced by trichlormethine in arm A, with addition of vinblastine to the 4-drug regimen in arm B, and alternation of three drugs--trichlormethine, vincristine, and prednisone--with probably non-cross resistant two drugs--vinblastine and procarbazine in arm C)." | ( Bohunický, L; Cerný, V; Gyárfás, J; Koza, I; Mardiak, J; Svancárová, L, 1989) |
| "Between 1979 and 1987, 28 children with Hodgkin's disease were treated with MOPP (nitrogen mustard, Oncovin, prednisone, procarbazine) combination chemotherapy without radiotherapy." | ( Madanat, FF, 1989) |
| "Twenty three patients with Hodgkin's disease were treated with BCNU (carmustine), etoposide, and cyclophosphamide at doses of 450-600 mg/m2, 1500-2000 mg/m2, and 120 mg/kg respectively." | ( Ahmed, T; Arlin, ZA; Ascensao, J; Ciavarella, D; Coleman, M; Engelking, C; Feldman, E; Gingrich, S; Hussain, F; Mittelman, A, 1989) |
| "Sixty-one patients with relapsed Hodgkin's disease who had failed a mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)- and a doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like regimen were treated with a high-dose combination chemotherapy containing cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation (ABMT)." | ( Armitage, JO; Dicke, KA; Hagemeister, FB; Horwitz, LJ; Jagannath, S; Kessinger, A; Smith, K; Tucker, SL; Vaughan, WP; Velasquez, WS, 1989) |
| "Thirty-one patients with resistant Hodgkin's disease were treated by an identical high dose chemotherapy regimen and autologous bone marrow transplantation." | ( Devereaux, S; Goldstone, AH; Gribben, JG; Linch, DC; McMillan, A; Patterson, K, 1989) |
| "Twenty patients with Hodgkin's disease which had relapsed at least once after chemotherapy, were treated with melphalan 140-220 mg/m2 i." | ( Ashley, S; Berry, J; Houwen, B; Jones, AR; Mbidde, EK; Poon, MC; Ruether, BA; Russell, JA; Selby, PJ; Zulian, G, 1989) |
| "Sixty patients with Hodgkin's disease were treated with a polychemotherapy regimen including very emetic dacarbazine and adriamycin in addition to bleomycin and vincristine on 622 treatment days during the last 10 years." | ( Berényi, E; Kiss, E, 1989) |
| "Chemotherapy of Hodgkin's lymphoma corrected the hypercalcaemia and subsequent exposure to UVR did not produce either hypercalcaemia or a high serum 1,25(OH)2D3." | ( Davies, M; Hayes, ME; Lumb, GA; Mawer, EB, 1985) |
| "391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia." | ( Ersbøll, J; Hansen, HH; Hansen, MM; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Specht, L; Struck, J, 1987) |
| "Occurrence of TM in non-Hodgkin's lymphoma has not previously been reported: its cause is uncertain; it may be to a late sequela of successful lymphoma chemotherapy." | ( Carey, RW; Harris, N, 1989) |
| "Two patients developed non-Hodgkin's lymphoma (NHL) six and ten years after radiotherapy and chemotherapy for Hodgkin's disease nodular sclerosis type." | ( Cuesta, B; Gómez-Bezares, MC; Idoate, MA; Marigil, MA; Pardo-Mindan, FJ; Rocha, E, 1986) |
| "A patient is described who developed Hodgkin's disease 16 years after treatment of Wilms' tumor with radiation and actinomycin D." | ( Bell, BA; Esseltine, DW; Freeman, CR, 1987) |
| "This article reports a patient with Hodgkin's disease in remission after combined modality therapy who developed metastatic pulmonary osteosarcoma, subsequently found to originate in soft tissue of the mediastinum, within a field irradiated 11 years previously." | ( Andres, DF; Catanese, J; Dorfman, HD; Dutcher, JP; Wiernik, PH, 1988) |
| "Fifty-three children with Hodgkin's disease were clinically staged and treated with chemotherapy alone." | ( Ekert, H; Mauger, D; Smith, PJ; Toogood, I; Waters, KD, 1988) |
| "In 10 patients with heavily pretreated Hodgkin's disease (stage IVA or IVB) a third-line salvage therapy consisting of CCNU, etoposide and chlorambucil (CECh) was tested." | ( Mödder, B; Ollenschläger, G; Schaefer, HJ, 1988) |
| "A total of 277 patients with untreated Hodgkin's disease, clinical stages I-II, were randomized to cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) alone for 6 monthly cycles or to CVPP plus radiation therapy (RT), 3,000 rad, to involved areas (CVPP plus RT)." | ( Corrado, C; Garcia, I; Magnasco, O; Maschio, M; Montero, C; Muriel, FS; Pavlovsky, S; Sanahuja, FL; Santarelli, MT; Schwartz, L, 1988) |
| "As in patients with Hodgkin's disease, an increase in erythrophagocytosis together with the prolonged retention of iron by RE cells appears to account for the accumulation of iron in the lymph nodes of trypan blue treated rats." | ( Dumont, AE, 1988) |
| "The patient was immunosuppressed due to Hodgkin's disease and treatment with cytotoxic chemotherapy." | ( Deakin, DP; Oppenheim, BA; Slevin, NJ, 1988) |
| "Patients with advanced Hodgkin's disease not achieving a complete remission with initial MOPP therapy are significantly less responsive to adriamycin and nitrosourea-containing regimens than patients with relapsing disease following a complete remission with MOPP." | ( Coleman, M; Friedlander, RJ, 1988) |
| "Two hundred ninety patients with Hodgkin's disease pathologic stage (PS) I or II were treated in the prospective randomized trial of the Danish National Hodgkin Study (see Appendix) with radiotherapy +/- adjuvant combination chemotherapy." | ( Clausen, NT; Cold, S; Nissen, NI; Nordentoft, AM; Specht, L, 1988) |
| "The H5 study of supradiaphragmatic Hodgkin's disease in clinical stages I-II consisted of two controlled trials adapted to patients considered to have either favorable or unfavorable characteristics, based on prognostic factors identified in two former studies by the European Organization for Research and Treatment of Cancer." | ( Burgers, JM; Carde, P; Cosset, JM; Hagenbeek, A; Hayat, M; Meerwaldt, JH; Monconduit, M; Sizoo, W; Somers, R; van der Schueren, E, 1988) |
| "We have described a patient with Hodgkin's disease who had fever and pulmonary infiltrates after treatment with mantle x-ray therapy and two courses of MOPP." | ( Davenport, OL; Huskison, WT; Wells, JD, 1986) |
| "In one patient with untreated Hodgkin's disease, temperature fell from 40." | ( Björkholm, M; Engervall, P; Grimfors, G; Holm, G, 1986) |
| "Eleven patients with Hodgkin's disease refractory to chemotherapy were treated with six cycles of intermediate-dose methotrexate with calcium leucovorin rescue, followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (MTX-CHOP)." | ( Garbes, ID; Gomez, GA; Han, T; Henderson, ES, 1987) |
| "Thirty patients with relapsed Hodgkin's disease were treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation." | ( Armitage, JO; Cabanillas, FF; Dicke, KA; Horwitz, LJ; Jagannath, S; Spitzer, G; Vellekoop, L; Zander, AR, 1986) |
| "Twenty-one patients with advanced non-Hodgkin's lymphoma or Hodgkin's disease who had failed to be cured with standard therapy were the subjects of this clinical trial." | ( Armitage, JO; Bierman, PJ; Gingrich, RD; Klassen, LW; Kumar, PP; Smith, DM; Weisenburger, DD, 1986) |
| "Of the 188 patients with Hodgkin's disease, 157 achieved a complete response (CR) (84%), and 66% of them (101 patients) have remained disease-free more than 10 years from the end of treatment." | ( DeVita, VT; Duffey, PL; Hubbard, SM; Jaffe, ES; Longo, DL; Wesley, M; Young, RC, 1986) |
| "299 patients with stage III or IV Hodgkin's disease were randomised to receive cyclical chemotherapy with MOPP (mustine, Oncovin, procarbazine, prednisone) or LOPP (Leukeran substituted for mustine)." | ( Hancock, BW, 1986) |
| "Nineteen patients with Hodgkin's disease who relapsed primarily in nodal sites after intensive combination chemotherapy were retreated with wide-field radiation therapy alone or with additional chemotherapy between January 1971 and December 1984." | ( Mauch, P; Rosenthal, D; Skarin, A; Tarbell, N; Weinstein, H, 1987) |
| "Forty-seven patients with Hodgkin's disease in relapse were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide)." | ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Riggs, S; Salvador, P; Tannir, N; Velasquez, WS, 1987) |
| "In 41 patients with Hodgkin's disease nitroblue tetrazolium (NBT) dye reduction with resting and stimulated granulocytes, before, in the course and after chemotherapy was examined." | ( Kemona, H; Kiluk, S; Prokopowicz, J; Wysocka, J, 1987) |
| "Thirty-two patients with recurrent Hodgkin's disease have been treated with an oral regimen employing lomustine (CCNU, 100 mg/m2 orally on Day 1); etoposide (VP-16, 100 mg/m2 orally on Days 1-3 and 21-23); and methotrexate (30 mg/m2 orally on Days 1, 8, 21, and 28)." | ( Coleman, CN; Horning, SJ; Jacobs, C; Lewis, BJ; Rosenberg, SA; Tseng, A, 1987) |
| "A case of recurrent Hodgkin's disease of the "sarcomatoid" or "syncytial variant" type was seen that occurred as an extension from the mediastinum to a previously uninvolved extranodal site (breast) and pericardium after treatment of classical nodular sclerosing Hodgkin's disease based in the lymph nodes." | ( Blaustein, JC; Lewkow, L, 1987) |
| "101 white British adults with Hodgkin's disease or non-Hodgkin's lymphoma were phenotyped for acetylation status using dapsone and for oxidation status with debrisoquine prior to treatment." | ( Harper, PG; Philip, PA; Rogers, HJ, 1987) |
| "Fifteen patients with Hodgkin's disease resistant to the chemotherapy combinations of cyclophosphamide, vinblastine, procarbazine and prednisone and doxorubicin, bleomycin, vinblastine, and dacarbazine were treated with lomustine, etoposide, and prednimustine." | ( Cervantes, F; Montserrat, E; Reverter, JC; Rozman, C, 1986) |
| "Seven patients with newly-diagnosed Hodgkin's disease, having standard mustine-vinblastine-prednisolone-procarbazine therapy, had a large and regular pattern of rise in SCE frequency in their peripheral lymphocytes, which apparently started to fall before the end of the course (32 wk)." | ( Brown, T; Bullock, I; Dawson, AA; King, DJ; Watt, JL, 1986) |
| "A patient seen at presentation for Hodgkin's disease (HD) at stage IV B was successfully treated with MOPP." | ( Eridani, S; Singh, AK, 1986) |
| "We report here a case of Hodgkin's disease that progressed untreated for almost four years by virtue of a delayed diagnosis before constitutional symptoms developed." | ( Haines, IE; Schwarz, MA, 1986) |
| "94 patients with Hodgkin's disease PS I or II, treated during the period 1969-78 and followed until death, or from 33 to 136 months after initiation of therapy, were analysed." | ( Nissen, NI; Specht, L, 1986) |
| "Three patients with remission of Hodgkin's disease after involved-field (two) and extended-field (one) radiotherapy died from cardiovascular disease that could only be attributed to the prior radiotherapy." | ( Caravelli, J; Cirrincione, C; Cunningham, I; Koziner, B; McCormick, B; Mertelsmann, R; Myers, J; Nisce, LZ; Redman, J; Straus, DJ, 1986) |
| "The results of treatment of I-II stage Hodgkin's disease in children aged 2-14 have been studied." | ( Chikrizov, SI; Kanaev, SV; Kolygin, BA; Malinin, AP, 1986) |
| "Seventeen patients with non-Hodgkin's lymphoma (NHL) and 2 patients with Hodgkin's disease (HD) were treated by combination chemotherapy (COPP or CHOP), and then received 300 X 10(4) U of alpha-IFN daily for 14 days." | ( Fukutani, H; Takeyama, H; Watanabe, E; Yano, K, 1987) |
| "A young man with Hodgkin's disease who experienced specific cutaneous ulcers over the scalp during treatment is described." | ( Jain, RK; Misra, RS; Mukherjee, A; Ramesh, V; Sharma, AK, 1987) |
| "Thirty-four patients with Hodgkin's disease and non-Hodgkin's lymphoma underwent therapeutic splenectomies to improve hematologic tolerance for chemotherapy." | ( Cox, RS; Hoppe, RT; Jacobs, C; Rosenberg, SA; Schreiber, DP, 1985) |
| "47 patients with advanced Hodgkin's disease (stage IIIB or IV) and mediastinal involvement, treated during the period 1969-78 and followed till death or from 36 to 126 months after initiation of therapy, were analysed." | ( Nissen, NI; Specht, L; Walbom-Jørgensen, S, 1985) |
| "Twenty-two patients with Hodgkin's disease were treated at Kanazawa University between 1975 and 1982." | ( Chohtoh, S; Hirose, J; Kamimura, R; Kobayashi, A; Nakamura, S; Nishijima, H; Ohtake, S; Saito, Y; Takashima, T; Yoshida, T, 1985) |
| "Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow." | ( Ersbøll, J; Keiding, N; Larsen, MS; Larsen, SO; Nissen, NI; Pedersen-Bjergaard, J; Philip, P; Schultz, H; Sørensen, HM, 1985) |
| "In 128 patients with Hodgkin's disease who had received various forms of treatment and who were studied at various stages of remission, HAA was found in the sera of 42 (33%)." | ( Barge, J; Degott, C; Erlinger, S; Grange, MJ; Schlegel, N; Teillet, F, 1973) |
| "Fifty-two patients with generalized Hodgkin's disease were treated with a combination of mustine hydrochloride, vinblastine, procarbazine, and prednisolone." | ( Beard, ME; Crowther, D; Fairley, GH; Malpas, JS; Nicholson, WM; Scott, RB; Stansfeld, AG; Vartan, CP, 1970) |
| "From 23 patients with advanced non-Hodgkin lymphomas of a high malignancy 11 received a therapy with CVPP scheme; 2 of them came into a complete remission and 3 of them into a partial one." | ( Anger, G; Fink, R; Höche, D, 1980) |
| "In 22 patients suffering from Hodgkin's disease with visceral lesions resistant to MOPP chemotherapy, the authors have tried a reserve treatment combining adriamycin, vinblastin, bleomycin and DTIC ("ABVD therapy")." | ( Amiel, JL; Ayed, FB; Brule, CH; Droz, JP; Tursz, T, 1980) |
| "One patient with Hodgkin's disease involving the liver is alive at 36 months with further therapy." | ( Gamble, JF; Loh, KK; Rodgers, RW; Shullenberger, CC, 1980) |
| "From 1970 to 1978 22 children with Hodgkin's lymphomas at the age of 4-15 years were treated at the university children's hospital of Jena." | ( Ahlendorf, W; Fuchs, D; Hermann, J; Plenert, W; Schickedanz, H; Stiller, D; Zintl, F, 1981) |
| "Lymphocyte depletion Hodgkin's disease (LDHD) was diagnosed in 8 of 40 children with Hodgkin's disease treated from July 1969 to September 1976." | ( Armata, J; Balwierz, W; Borkowski, W; Depowska, T, 1981) |
| "Patients with Hodgkin's disease (stage IIIB and IV) after being rendered with combination chemotherapy disease-free, were alternatively allocated to either a group receiving levamisole treatment (Decaris) or to a control group receiving no further therapy until there was evidence of recurrent disease." | ( Donner, L; Hausner, P; Klener, P, 1982) |
| "Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD)." | ( Bond, WH; Chenoweth, L; Einhorn, LH; Stevens, EE; Williams, SD, 1983) |
| "Fourteen patients with Hodgkin's disease resistant to ABVD were treated with MOPP chemotherapy (nitrogen mustard, vincristine, procarbazine, prednisone)." | ( Anselmo, AP; Cimino, G; Mandelli, F; Marzullo, A; Maurizi Enrici, R; Mauro, F; Papa, G, 1983) |
| "Seven patients with active Hodgkin's lymphoma who had relapsed 4-39 months following six or more cycles of MOPP were treated with a combination of vinblastine-bleomycin-cis-platin (VBP)." | ( Clamon, GH; Corder, MP; Wiesenfeld, M, 1984) |
| "Although most patients with Hodgkin's disease refractory to MOPP treatment will respond to either ABVD or B-CAVe chemotherapy, subsequent long-term disease-free survival is unusual." | ( Harker, WG; Kushlan, P; Rosenberg, SA, 1984) |
| "Untreated patients with Hodgkin's disease are known to have significant impairment of cellular immunity." | ( Fisher, RI, 1982) |
| "Prognosis and proper treatment in Hodgkin's disease (HD) are strictly related to staging accuracy: liver and spleen involvement is of particular importance in this regard." | ( Cellerino, R; Cetto, G; Martinelli, L; Miseria, S; Perona, G; Tummarello, D, 1984) |
| "The results of 111 children with Hodgkin's disease, who were treated with chemotherapy of different intensity and reduced radiotherapy (Cooperative Therapy Study HD 82, 12/81 - 9/83) are presented." | ( Schellong, G; Strauch, S; Wannenmacher, M, 1984) |
| "Three of four patients with Hodgkin's disease responded after relatively short periods of treatment." | ( Axelson, JA; Charamella, LJ; Clark, RH; Dimitrov, NV, 1984) |
| "A 30 years old man having Hodgkin's disease was treated successfully by means of chemotherapy and radiotherapy." | ( Callén, L; Fuertes, MA; Gutiérrez, M; Peleato, A; Poderós, C; Polo, J; Rodrigo, G; Tres, A, 1984) |
| "Twenty-seven children with Hodgkin's disease were treated with MVOPP (mustine, Velban [vinblastine], Oncovin [vincristine], procarbazine, prednisone) combination chemotherapy." | ( Hartley, P; Jacobs, P; Karabus, C; King, HS; Werner, D, 1984) |
| "The example of Hodgkin's lymphoma staging and treatment selection is used." | ( Corder, MP; Ellwein, LB, 1984) |
| "Of 209 Hodgkin's disease patients treated at least 6 months with a five-drug combination of induction chemotherapy and having a complete remission, four patients developed acute myelogenous leukemia (AML) as a second malignant neoplasm." | ( Bartolucci, AA; Durant, JR; Gams, RA; Liu, C, 1983) |
| "In 164 patients with Hodgkin's disease staged between 1973 and 1979 the response to the 3 initial cycles of multiagent chemotherapy was evaluated as a prognosticator of survival." | ( Bierling, P; Brun, B; Dreyfus, B; Farcet, JP; Imbert, M; Kuentz, M; Le Bezu, M; Lebourgeois, JP; Reyes, F; Rochant, H; Vernant, JP, 1983) |
| "Of 157 patients with Hodgkin's disease treated between 1970 and 1981 an assessment of the clinical course was possible in 134 cases." | ( Denz, H; Huber, H; Lechleitner, M; Peer, L; Peschel, C, 1983) |
| "A 26-year-old woman with Hodgkin's disease had recurrent episodes of meningitis caused by Salmonella enteritidis serotype poona, which responded well to antimicrobial therapy." | ( Bodey, GP; Bolivar, R; Velasquez, WS, 1982) |
| "Seven patients treated for Hodgkin's disease by chemotherapy and radiotherapy developed avascular necrosis of the heads of long bones (femur in six cases, humerus in one case)." | ( Adam, NM; Mould, JJ, 1983) |
| "Six patients with Hodgkin's disease who failed MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy, with recurrences confined to lymph node areas, are reported." | ( Baldwin, PE; Diehl, LF; Dorn, RV; Hurwitz, M; Kimball, DB; Perry, DJ; Terebelo, H, 1983) |
| "Advanced Hodgkin's disease appears to be curable by chemotherapy." | ( Berard, CW; Canellos, GP; Carbone, PP; DeVita, VT; Frei, E; Hubbard, SM; Moxley, JH; Simon, RM; Young, RC, 1980) |
| "The dose of combination chemotherapy in Hodgkin's disease is commonly calculated from a formula based on the body surface area." | ( Dawson, AA; Fell, LF; Green, JA; Murray, S, 1980) |
| "50 patients with Hodgkin's disease were treated with MOPP chemotherapy." | ( Neumann, E, 1981) |
| "Thirty-six patients with advanced Hodgkin's disease who were treated primarily with MOPP were evaluated to determine the reasons for MOPP failure." | ( Armitage, JO; Corder, MP, 1982) |
| "Thirty seven Hodgkin's lymphoma patients with recurrence after first remission induced by radiation therapy and/or chemotherapy with mustine, oncovin, procarbazine and prednisolone (MOPP) were randomised to treat with a new combination chemotherapy comprising of doxorubicin, oncovin, procarbazine and prednisolone (DOPP)." | ( Ahmed, Q; Rahim, MA; Sarma, SK, 1982) |
| "A patient with Hodgkin's disease developed acute radiation pneumonia four months after completion of mantle radiotherapy and during cyclical adjuvant chemotherapy." | ( Manoharan, A; Schonell, M, 1980) |
| "A case of Hodgkin's disease is reported in which acute promyelocytic leukaemia developed within 5 months of initiation of chemotherapy." | ( King, JB; Rosenstrauch, WJ; Steytler, JG; van der Merwe, AM; van Eeden, PJ, 1980) |
| "Patients treated for Hodgkin's disease are exposed to increased risk for second malignancies, a fact which has been well documented in the past decade." | ( Bamberg, M; Donhuijsen, K, 1981) |
| "In 40 cases of Hodgkin's disease (24 untreated patients and 16 patients in remission) the immunological humoral and cell-mediated competence was studied using test of hypersensitivity of DNCB and PPD, blastic transformation and the ability of 3H-DNA synthesis in lymphocytes stimulated with PHA and PWM, and in some cases, with PPD." | ( Arczyńska-Brojer, E; Cieśluk, S; Karpowicz, M; Konopka, L; Maślanka, K; Małkowska-Zwierz, W; Pawelski, S; Sylwestrowicz, T; Traczyk, Z; Zywicka-Lopaciuk, H, 1980) |
| "We conclude that (1) survival of Hodgkin's disease of childhood has shown a rather marked improvement during the last decade and this progress is probably due to the use of combined multidrug chemotherapy administered under collaborative controlled clinical trials; (2) preliminary evaluation of the results of CVPP and CCVPP therapy shows that the latter combination (CCVPP) neither increases the percent of patients achieving complete remission nor prolongs relapse-survival in Hodgkin's disease of childhood: and (3) all stages of childhood Hodgkin's disease can be successfully managed with multidrug chemotherapy alone." | ( Bonesana, AC; Kvicala, R; Morgenfeld, M; Ojeda, F; Papendieck, C; Pavlovsky, S; Penchansky, L; Sackmann-Muriel, F; Schwartz, L; Sica, M, 1981) |
| "Since 1975, 191 patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP)." | ( Austin, DE; Barrett, A; Dady, PJ; McElwain, TJ; Peckham, MJ, 1982) |
| "Eleven untreated patients with non-Hodgkin's lymphomas and 21 healthy persons were used as controls." | ( Björkholm, M; Holm, G; Johansson, B; Lindemalm, C; Mellstedt, H, 1982) |
| "Thirty-eight patients with advanced Hodgkin's disease were treated with a combination of cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP); the minimum period of observation for surviving patients was five years." | ( Bloomfield, CD; Gibbs, GE; Kennedy, BJ; Peterson, BA; Vosika, G, 1981) |
| "On investigation, stage IIIb Hodgkin's disease was diagnosed and responded well to chemotherapy with a remission lasting now for 2 years." | ( Graf, W; Stäubli, M; Straub, PW, 1981) |
| "Stage II Hodgkin's disease probably should be divided into two substages requiring different treatment." | ( Streuli, RA; Ultmann, JE, 1981) |
| "A total of 44 patients with Hodgkin's disease and 23 patients with non-Hodgkin malignant lymphoma were treated with MOPP-combination chemotherapy." | ( Andersen, E; Videbaek, A, 1980) |
| "Diagnosis of Hodgkin's disease was made in a patient who had been treated with diphenylhydantoin sodium for 4 years." | ( Bladé Creixenti, J; García San Miguel, J; Nogué Xarau, S; Segura Porta, F; Soriano Marín, E, 1980) |
| "58 patients with early stages of Hodgkin's disease (I, II, III l) were treated by 3 courses of MOPP chemotherapy followed by extended field irradiation." | ( Alaoui, Y; Baillet, F; Brun, B; Dreyfus, B; Kuentz, M; Maylin, C; Pierquin, B; Reyes, F; Rochant, H; Vernant, JP, 1980) |
| "In 5 patients (2 with Hodgkin's disease and 3 with non-Hodgkin's lymphoma) who had high fever, after treatment the temperature decreased down to 34." | ( Gabryś, K; Mazur, G, 1995) |
| "28 patients suffering from advanced Hodgkin's disease were treated according to protocol containing 7 cytostatic drugs including methotrexate and corticosteroids, but not cyclophosphamide, chlormethine or procarbazine." | ( Gabryś, K; Kotlarek-Haus, S; Potoczek, S, 1995) |
| "80% or more of patients suffering from Hodgkin's lymphoma (HD) of limited stage are cured with modern treatment." | ( Glanzmann, C; Stahel, R, 1995) |
| "Recurrent Hodgkin's Disease (HD) provides unique opportunities to improve radiolabeled immunoglobulin therapy (RIT)." | ( Morton, JD; Quadri, SM; Vriesendorp, HM, 1995) |
| "A retrospective review of patients with Hodgkin's disease treated at Stanford University Medical Center was undertaken to determine if, within the pediatric population, children < or = 10 years of age have a unique prognosis and response to treatment." | ( Cleary, SF; Donaldson, SS; Link, MP, 1994) |
| "Records of all patients treated for Hodgkin's disease at SUMC between 1961 and 1991 were reviewed." | ( Cleary, SF; Donaldson, SS; Link, MP, 1994) |
| "Patients whose Hodgkin's disease is refractory to standard combination chemotherapy usually have a poor prognosis." | ( al-Katib, A; Andersen, J; Bishop, CR; Hussein, ME; Karanes, C; Khanuja, PS; Smith, MR, 1994) |
| "Management of Hodgkin's disease (HD) and large mediastinal adenopathy (LMA) usually includes intensive chemotherapy (CT) with or without radiation therapy (XT) regardless of stage." | ( Allen, PK; Besa, P; Cabanillas, F; Cox, JD; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, A; Swan, F, 1994) |
| "Of our 19 patients with Hodgkin's disease (age range, 6 to 20 years) treated with this regimen, 2 had clinical stage I disease, 10 had stage II, 6 had stage III, and 1 had stage IV." | ( Arndt, CA; Chen, MG; Gilchrist, GS; Khan, SP; Matsumoto, JM; O'Fallon, WM; Schomberg, PJ; Smithson, WA, 1994) |
| "Twenty-four patients with Hodgkin's disease refractory or resistant to at least two chemotherapy regimens were enrolled in this study." | ( Balzarini, L; Bonadonna, G; Bonfante, V; Devizzi, L; Santoro, A; Valagussa, P; Viviani, S, 1994) |
| "We report a 54-year-old patient with Hodgkin's disease who achieved a complete remission after combined modality treatment." | ( Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL, 1995) |
| "Patients with Hodgkin's disease (HD) who fail to enter a complete remission after an initial course of combination chemotherapy are usually considered to have an induction failure (IF); this subset of patients has an extremely poor outcome with further conventional therapy." | ( Barnett, MJ; Fairey, RN; Hogge, DE; Klasa, RJ; Klingemann, HG; Nantel, SH; Reece, DE; Shepherd, JD; Sutherland, HJ; Voss, NJ, 1995) |
| "Patients with Hodgkin's or non-Hodgkin's lymphoma are staged for treatment based on the extent of known disease involvement and the histopathologic grading of the disease." | ( Goldsmith, SJ; Macapinlac, HA; O'Brien, JP, 1995) |
| "Patients with treated Hodgkin's lymphoma (HL, n = 20, 68 malignant lesions, three benign lesions) or non-Hodgkin's lymphoma (NHL, n = 26, 46 malignant lesions, one benign lesion) were studied with positron emission tomography (PET) and fluorine-18 deoxyglucose (FDG)." | ( Dimitrakopoulou-Strauss, A; Goldschmidt, H; Lorenz, WJ; Maier-Borst, W; Strauss, LG; van Kaick, G, 1995) |
| "In successfully treated patients with Hodgkin's disease the described changes are of minor significance." | ( Behles, C; Kreuser, ED; Schröder, K; Schröder, R; Thiel, E; Uhrig, A; Völler, H, 1993) |
| "Treatment of Hodgkin's disease resulted in complete remission and complete disappearance of the pontine abnormality." | ( Carrol, CL; Chintagumpala, MM; Dreyer, ZE; Fishman, MA; Mahoney, DH; McClain, K; Steuber, CP, 1993) |
| "Treatment results of Hodgkin's disease have been improved by polychemotherapy." | ( Diehl, V, 1993) |
| "Between 1980 and 1988, 48 patients with Hodgkin's disease who had large mediastinal masses were treated at Stanford University." | ( Behar, RA; Hoppe, RT; Horning, SJ, 1993) |
| "Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents." | ( Hagemeister, FB, 1993) |
| "Anderson Cancer Center for treatment of Hodgkin's disease [HD]." | ( Bailey, NM; Cabanillas, FF; Fuller, LM; Gabriel, GJ; Hagemeister, FB; Kattan, MW; Liang, JC; Wang, RY, 1993) |
| "60 cases of Hodgkin's lymphoma were treated with combined chemotherapy and radiotherapy." | ( Wang, H; Yong, WB; Zhu, XM, 1993) |
| "Patients with Hodgkin's disease whose initial complete remissions (CR) after primary chemotherapy were longer than 1 year are thought to have better prognoses than patients whose initial remissions were shorter than 1 year." | ( Aversa, SM; Bianco, A; Chiarion Sileni, V; Fiorentino, MV; Pappagallo, GL; Salvagno, L; Sorarù, M, 1993) |
| "Patients with Hodgkin's disease were treated with ChlVPP chemotherapy: days 1-14: chlorambucil: 6 mg/m2/day, procarbazine: 100 mg/m2/day, prednisone or prednisolone: 40 mg/day; Days 1, 8: vinblastine: 6 mg/m2/day." | ( , 1995) |
| "Fifty-six patients with non-Hodgkin's lymphoma (NHL, n = 26), Hodgkin's disease (HD, n = 17), or acute lymphoblastic leukemia (ALL, n = 13) with a history of previous radiation therapy were treated with cyclophosphamide (7." | ( Anasetti, C; Bensinger, WI; Buckner, CD; Clift, RA; Demirer, T; Lilleby, K; Martin, P; Petersen, FB; Sanders, J; Weaver, CH, 1995) |
| "Although initial treatment of Hodgkin's disease induces a complete remission in most patients, approximately 50% of patients with advanced disease will not achieve a complete remission or will relapse following the first complete remission." | ( Ammendolia, I; Babini, L; Barbieri, E; Bendandi, M; Fiacchini, M; Gherlinzoni, F; Neri, S; Perini, F; Salvucci, M; Zinzani, PL, 1994) |
| "Patients with PSIII 1A Hodgkin's disease treated with RT have a significantly higher risk of relapse and potentially a poorer survival compared with patients treated with CMT." | ( Canellos, GP; Coleman, CN; Kalish, LA; Marcus, KC; Mauch, PM; Rosenthal, DS; Shulman, LN, 1994) |
| "A substantial number of patients with Hodgkin's disease (HD) do not respond adequately to standard therapy." | ( de Pauw, BE; Jongen-Lavrencic, M; Raemaekers, JM; Vreugdenhil, G, 1994) |
| "Advanced stage Hodgkin's disease (HD) usually is treated with combination chemotherapy with or without supplemental irradiation." | ( Brizel, DM; Crawford, J; Gockerman, JP; Hathorn, JW; Moore, JO; Osborne, B; Prosnitz, LR, 1994) |
| "Fifty-one consecutive patients with Hodgkin's disease (HD) have been treated with high-dose chemotherapy (HDT) and transplantation of autologous bone marrow (BM) (n = 44), autologous BM plus peripheral blood stem cells (PBSC) (n = 2), PBSC (n = 1), syngeneic (n = 1), or allogeneic BM (n = 3)." | ( Dreger, P; Gassmann, W; Glass, B; Haferlach, T; Horst, HA; Löffler, H; Ollech-Chwoyka, J; Schmitz, N; Suttorp, M, 1993) |
| "Patients with advanced Hodgkin's disease failing to achieve complete remission with chemotherapy or developing disease progression within 1 year have a poor prognosis with salvage chemotherapy." | ( Fairey, AF; Jones, HW; Mead, GM; Sweetenham, JW; Whitehouse, JM, 1993) |
| "Twenty-four patients with Hodgkin's disease were treated with high-dose chemotherapy and ABMT." | ( Bennett, C; Gopal, A; Gopal, R; Gulati, S; Toia, M, 1993) |
| "We present 155 poor-risk Hodgkin's disease patients who received high-dose BEAM (BCNU, etoposide, cytosine arabinoside, and melphalan) chemotherapy and ABMT who have been studied over a period of 8 years." | ( Chopra, R; Goldstone, AH; Linch, DC; McMillan, AK; Patterson, KG; Pearce, R; Taghipour, G; Yuklea, S, 1993) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "Twenty-one patients with relapsed Hodgkin's disease that had progressed after both MOPP-like and ABVD-like regimens were treated with CBV plus cisplatin (90 mg/m2) and ABMT." | ( Cabanillas, F; Dicke, KA; Hagemeister, F; Horwitz, LJ; Jagannath, S; Spinolo, JA; Spitzer, G; Velásquez, W, 1993) |
| "Seventy-three patients with advanced Hodgkin's disease who had failed to achieve remission with front-line chemotherapy (n = 16) or who had relapsed (n = 57) were treated with high-dose etoposide 60 mg/kg and melphalan 160 mg/m2 and ABMT." | ( Brandwein, J; Couture, F; Crump, M; McCrae, J; Murray, C; Pantalony, D; Scott, JG; Sherret, H; Smith, AM; Sutton, DM, 1993) |
| "Relapsed or refractory Hodgkin's disease (HD) patients were treated with an intensive salvage regimen (MINE) prior to high-dose therapy (HDT) with hematopoietic stem cell support." | ( Bastion, Y; Berger, F; Brice, P; Chéron, N; Fermé, C; Gabarre, J; Lepage, E; Morel, P; Nédellec, G; Reman, O, 1995) |
| "Treatment of both Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL) with bulky presentation at diagnosis frequently results in residual masses detected radiologically." | ( Babini, L; Barbieri, E; Battista, G; Bendandi, M; Canini, R; Fanti, S; Frezza, G; Gherlinzoni, F; Gozzetti, A; Merla, E; Monetti, N; Pisi, P; Rimondi, MR; Tura, S; Zinzani, PL; Zompatori, M, 1996) |
| "Patients with Hodgkin's disease (HD) were randomly selected before, during or after the completion of combined chemotherapy." | ( Ivanov, VT; Karelin, AA; Philippova, MM; Pivnik, AV; Rasstrigin, NA, 1996) |
| "In most patients with newly diagnosed Hodgkin's disease, initial therapy is curative." | ( Horning, SJ; Yuen, AR, 1996) |
| "We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine." | ( Knowles, SR; Poldre, P; Shapiro, L; Shear, NH, 1996) |
| "Subsequently, standard chemotherapy for Hodgkin's disease induced complete clinical and biochemical remission." | ( Jensen, MK; Johansen, P; Pulczynski, S, 1996) |
| "Histologic features of recurrent Hodgkin's disease (HD) after conventional therapy are well known, but few studies describe HD after bone marrow transplantation (BMT)." | ( Beeker, TA; Collins, RD; Cousar, JB; Greer, JP; Shahab, I; Wolff, SN, 1997) |
| "Eighty patients with refractory Hodgkin's disease were treated with radiolabeled antiferritin." | ( Cromeens, DM; Freedman, RS; Jaeckle, KA; Quadri, SM; Vriesendorp, HM, 1996) |
| "Accurate staging of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) is important for treatment management." | ( Dahlbom, M; Glaspy, J; Hawkin, RA; Hoh, CK; Kunkel, L; Lee, SJ; Maddahi, J; Phelps, ME; Rosen, P, 1997) |
| "20 patients in early stages (I-IIB) Hodgkin's disease were treated with smaller than commonly used doses of cytostatics and radiation." | ( Dubowik, R; Gabryś, K; Urbaniak-Kujda, D, 1996) |
| "Thirty untreated patients with advanced Hodgkin's disease stage IIB IV according to the Ann Arbor classification were treated with the time intensified BEACOPP regimen." | ( Adler, M; Diehl, V; Hasenclever, D; Koch, P; Lathan, B; Lieberz, D; Loeffler, M; Pfreundschuh, M; Rüffer, U; Sieber, M; Tesch, H, 1997) |
| "Patients treated for Hodgkin's disease and non-Hodgkin lymphomas were followed for 5 years after start of therapy." | ( Keinànen, S; Laine, P; Lindqvist, C; Meurman, JH; Pyrhönen, S; Teerenhovi, L, 1997) |
| "Patients with Hodgkin's disease have higher a prevalence of thyroid function abnormalities and, perhaps, orbitopathy than the general population, but the pathophysiology of this association and its relationship to Hodgkin's disease treatment remain unclear." | ( Barsouk, A; Burman, KD; Diehl, L; Freter, CE; Howard, RS; Ringel, MD; Taylor, T; Wall, JR, 1997) |
| "Asymptomatic patients with Hodgkin's disease involving at most one extranodal site whose disease is controlled by conventional dose chemotherapy or radiation therapy at the time of HDC have good outcomes after this therapy." | ( Antin, J; Antman, K; Ault, K; Ayash, L; Bierer, B; Churchill, WH; Eder, JP; Eickhoff, C; Elias, A; Ferrara, J; Frei, E; Gaynes, L; Gilliland, G; Guinan, E; Ibrahim, J; Kadin, M; Mauch, P; Mazanet, R; McCauley, M; Parsons, S; Rimm, IJ; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1997) |
| "Sixteen patients with Hodgkin's disease were treated with MOPP/ABVD and filgrastim support between January 1992 and March 1994." | ( Gustavsson, A, 1997) |
| "Previous studies have shown that in non-Hodgkin's lymphomas and others neoplasms, tumoral progression, treatment response, and outcome are related to the expression of different oncogenic and tumor suppressor proteins." | ( Abraira, V; Acevedo, A; Aguilera, B; Bellas, C; Fraga, M; Garcia-Del-Moral, R; Gomez-Marcos, F; Menarguez, J; Montalban, C; Morente, MM; Oliva, H; Piris, MA; Sanchez-Beato, M, 1997) |
| "The authors describe a patient with Hodgkin's disease who developed an atypical aortic dissection while receiving MOPP/ABV chemotherapy (nitrogen mustard, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine)." | ( Bavaria, JE; Crooks, GW; Golden, MA; Holland, GA; Vaughn, DJ, 1997) |
| "Most cases of Hodgkin's disease (HD) are responsive to combination chemotherapy regimes that include topo II poisons such as doxorubicin." | ( Brown, MS; Holden, JA; Perkins, SL; Rahn, MP, 1998) |
| "The treatment of Hodgkin's disease (HD) at advanced stages relies mainly upon multi-agent chemotherapies (CT), while the role of radiation therapy has not been definitely identified." | ( Andrieu, JM; Brière, J; Casassus, P; Colonna, P; Desablens, B; François, S; Ghandour, C; Guilhot, F; Harousseau, JL; Jais, JP; Le Prisé, PY; Lejeune, F; Lemevel, A, 1998) |
| "Patients treated with radiotherapy for Hodgkin's disease have a considerable risk for a second cancer in long-term follow-up." | ( Joensuu, H; Muhonen, T; Nyandoto, P, 1998) |
| "Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses." | ( Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J, 1998) |
| "Patients treated for Hodgkin's disease have an increased risk of developing subsequent acute leukemia." | ( Anselmo, AP; Baroni, CD; Bernasconi, C; Brusamolino, E; Klersy, C; Lazzarino, M; Lunghi, F; Mandelli, F; Maurizi-Enrici, R; Orlandi, E; Pagnucco, G; Santoro, M, 1998) |
| "The patients with advanced-stage Hodgkin's disease who did not achieve a complete remission from their initial treatment with combination chemotherapy have a dismal prognosis." | ( Shimoyama, M; Tsushita, K; Utsumi, M, 1998) |
| "In the treatment of Hodgkin's disease (HD) remission rates of 80% have been achieved with combination regimens such as COPP/ABVD; 30%-50% of these patients relapse, however, and less than 25% of those in first relapse can be cured." | ( Borchmann, P; Diehl, V; Engert, A; Schnell, R, 1998) |
| "72 patients (41 non-Hodgkin lymphomas, 29 Hodgkin's disease, 2 unclassified) received static FDG-PET scans of initially involved regions (n = 53) or of the entire neck and trunk (n = 19) after therapy." | ( Büll, U; Cremerius, U; Fabry, U; Kröll, U; Neuerburg, J; Osieka, R; Zimny, M, 1999) |
| "Six patients with high-risk Hodgkin's disease (HD) (5 untreated cases with bulky mass and 1 relapsed case) received G-CSF (5 micrograms/kg) subcutaneously from day 8 to day 13 of their first course of ABVD treatment; the numbers of CD34+ cells and CFU-GM were monitored." | ( Iwase, O; Katagiri, T; Kimura, Y; Miyazawa, K; Nakano, M; Nishimaki, J; Suzuki, A; Syoji, N; Toyama, K, 1999) |
| "Patients with Hodgkin's disease, which is either refractory or recurs after frontline chemotherapy with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone), ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or both regimens, generally have a poor prognosis." | ( Andersson, B; Cabanillas, F; Fayad, L; Hagemeister, FB; McLaughlin, P; Rodriguez, J; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F, 1999) |
| "Patients affected by Hodgkin's disease (HD) in pathologic stage IA-IIA have a strong possibility of remission and long-term survival when treated with radiotherapy to extended fields." | ( Anselmo, AP; Donato, V; Enrici, RM; Falchetto Osti, M; Mandelli, F; Santoro, M; Tombolini, V, 1999) |
| "Cytostatic therapy of Hodgkin's disease had ovariotoxic effects and led to amenorrhea in 83% of the examinees." | ( Ignashina, EV; Margolin, OV; Pivnik, AV; Rasstrigin, NA; Shilin, DE, 1999) |
| "Optimal treatment for Hodgkin's disease during childhood is unknown." | ( Farah, RA; Geara, F; Hajjar, T; Khogali, M; Muwakkit, S; Nabbout, B; Shabb, NS, 1999) |
| "Thirty-two patients (15 with Hodgkin's disease (HD) and 17 with aggressive histology non-Hodgkin's lymphoma (NHL)) who had residual masses on their post-treatment CT scans underwent 18-FDG-PET." | ( Hain, SF; Mikhaeel, NG; O'Doherty, MJ; Timothy, AR, 2000) |
| "The treatment of advanced Hodgkin's disease (HD) with chemotherapy (CTx) alone or combined modality treatments has been controversial." | ( Berger, F; Bordessoule, D; Brice, P; Caillot, D; Diviné, M; Fermé, C; Ferrant, A; Gabarre, J; Hennequin, C; Lederlin, P; Lepage, E; Moullet, I; Sebban, C, 2000) |
| "Sixteen patients (15 Non-Hodgkin's, 1 Hodgkin's Disease) were entered into a phase II study to determine if a dose intensive induction regimen in heavily pre-treated refractory lymphoma patients could permit further consolidation with HPCT." | ( Devine, S; Heffner, LT; Jones, TW; Lonial, S; Smith, KJ; Waller, EK; Winton, EF; Yeager, AM, 2000) |
| "29 patients (12 Hodgkin's disease, 17 non-Hodgkin's lymphoma (NHL)) who underwent FDG-PET imaging during their lymphoma treatment programme were reviewed retrospectively." | ( Gibson, P; Hoskin, P; Lowe, J; McMillan, A; Shah, N; wong, WL, 2000) |
| "Modern chemotherapy programs for Hodgkin's lymphoma include virtually all active agents and little is left for effective salvage." | ( Kraszewska, E; Krzyzanowska, JB; Lampka, E; Meder, J; Miśkiewicz, Z; Romejko-Jarosińska, J; Walewski, J, 2000) |
| "46 patients with Hodgkin's disease received Dexa-BEAM chemotherapy followed by radiotherapy." | ( Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL, 2000) |
| "In early-stage Hodgkin's disease, four cycles of ABVD followed by adjuvant radiotherapy produced a 5-year overall survival of 98%." | ( Astori, C; Baio, A; Baraté, C; Bernasconi, C; Brusamolino, E; Franchini, P; Lazzarino, M; Lunghi, F; Orlandi, E; Pagnucco, G; Passamonti, F, 2000) |
| "Six patients with advanced Hodgkin's disease in which multiple conventional treatments (median prior chemotherapy regimens: seven), radiation therapy, and a prior autologous stem cell transplantation (SCT) had failed underwent allogeneic SCT following a fludarabine-based conditioning regimen." | ( Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT, 2000) |
| "Patients with Hodgkin's disease (HD) refractory to first line chemotherapy and those who have rapid or multiple relapses have a very poor prognosis." | ( Angus, B; Carey, PJ; Finney, RD; Galloway, MJ; Goff, DK; Haynes, A; Jackson, GH; Lennard, AL; Leonard, RC; McQuaker, IG; Proctor, SJ; Russell, N; Taylor, PR; Windebank, K, 2000) |
| "Optimum therapy for patients with Hodgkin's disease (HD) is determined by a number of prognostic factors, one of which is an accurate definition of extent of disease (stage)." | ( Hain, SF; Mikhaeel, G; O'Doherty, MJ; Partridge, S; Rankin, S; Timothy, A, 2000) |
| "In 1995-1999, 67 patients with relapsed Hodgkin's disease or refractory to chemotherapy (group A--first relapse, B--primary refractory disease, and C--repeated relapse) received cytoreductive (dexaBEAM, DHAP) therapy followed by high-dose BEAM chemotherapy and autologous bone marrow or blood cell transplantation." | ( Aleĭnikova, OV; Batan, ZE; Dziuba, EV; Milanovich, NF; Mitskevich, PB; Skriagin, AE; Solov'eva, NS; Uss, AL; Vlasenkova, SV; Zavgorodniaia, IL; Zhavrid, EA; Zmachinskiĭ, VA, 2000) |
| "A typical dilemma after treatment of Hodgkin's disease with radiographically persistent lymphoma is the differentiation between sterilized residual mass and viable tumor." | ( Bihl, H; Hültenschmidt, B; Lang, O; Sautter-Bihl, ML, 2001) |
| "In a patient with Hodgkin's disease who failed to achieve complete remission with the escalated BEACOPP protocol, progression with bone marrow infiltration and B symptoms developed despite further treatment." | ( Eucker, J; Jakob, C; Kaufmann, O; Possinger, K; Schmid, P; Sezer, O, 2001) |
| "Development of non-Hodgkin's lymphoma (NHL) in people with AIDS is addressed, focusing on prevalence; symptoms; etiology; and current advances in treatment options." | ( Majchrowicz, M, 1995) |
| "Fifty-six patients with stage I or II Hodgkin's lymphoma treated with ABVD were eligible for secondary prophylactic G-CSF administration because of neutropenia (absolute neutrophil count < 1 x 10(9) /L) causing treatment delay or febrile neutropenia." | ( Alba, E; De Las Nieves, MA; Gumà, J; Márquez, A; Miramón, J; Ribelles, N; Rueda, A; Sevilla, I, 2001) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "Thirty-three evaluable patients with Hodgkin's disease who failed radiotherapy were treated on this phase II study with bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone given every 28 days for a minimum of eight courses." | ( Bennett, JM; Glick, JH; Habermann, TM; Leong, T; Neiman, RS; Oken, MM; Schuster, S; Wiernik, PH, 2001) |
| "A 12-year-old boy with Hodgkin's disease developed left peroneal nerve palsy during combination therapy with chemotherapy and low-dose irradiation." | ( Baba, K; Harigaya, H; Matsubara, K; Nigami, H; Osaki, M, 2000) |
| "We report on a patient with Hodgkin's disease who presented with hypodense splenic lesions and corresponding increased glucose metabolism in FDG-PET imaging, four months after completion of initial treatment, suggestive of early relapse." | ( Avril, N; Link, T; Peschel, C; Sandherr, M; Stock, K; von Bubnoff, N; von Schilling, C, 2001) |
| "Successful treatment of advanced-stage Hodgkin's disease (HD) may critically depend on dose intensity." | ( Barcos, M; Cooper, MR; Frei, E; Johnson, JL; Lester, EP; Millard, FE; Omura, GA; Peterson, BA; Petroni, GR, 2001) |
| "We report a patient treated for Hodgkin's disease by 6 ABVD and total lymphoid radiation therapy, who developed a gastric carcinoma 9 years after completing treatment." | ( el Omri, H; Ennabli, S; Korbi, S; Kraiem, I; Skouri, H; Sriha, B; Youssef, YB, 2001) |
| "HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment." | ( Aranha, JF; Baldissera, RC; De Souza, CA; Eid, KA; Miranda, EC; Oliveira, GB; Vigorito, AC, 2002) |
| "Approximately 75% of patients with Hodgkin's lymphoma can be cured with modern chemotherapy and radiation." | ( Fung, HC; Nademanee, AP, 2002) |
| "Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571." | ( Ahmadi, T; Buchdunger, E; Diehl, V; Kochanek, M; Re, D; Wickenhauser, C; Wolf, J, 2002) |
| "Four of five patients with Hodgkin's disease (HD) will be cured with modern treatment strategies, depending on stage and risk factor profile." | ( Diehl, V; Glossmann, JP; Josting, A, 2002) |
| "Survivors of childhood Hodgkin's lymphoma (HL) have an increased risk of developing treatment-related complications, especially second malignant neoplasms, as a result of treatment regimens incorporating chemotherapy and radiation therapy." | ( Kelly, KM; Perentesis, JP, 2002) |
| "Fifty-nine patients with Hodgkin's disease or aggressive non-Hodgkin's lymphoma presenting abdominal involvement (35% with bulky disease) were studied with both PET and CT following combined chemotherapy/radiation treatment." | ( Albertini, P; Alinari, L; Baccarani, M; Chierichetti, F; Ferlin, G; Garraffa, G; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zompatori, M, 2002) |
| "Therapy for the Hodgkin lymphoma with chemotherapy was initiated." | ( Dumoulin, FL; Fischer, HP; Platen, E; Sauerbruch, T, 2002) |
| "The staging of Hodgkin's lymphoma (HL) is crucial for an optimal therapy, and fluorine-18-deoxyglucose-positron emission tomography (FDG-PET) is increasingly used in this regard." | ( Berner, U; Diehl, M; Döbert, N; Grünwald, F; Menzel, C; Mitrou, P; Mose, S, 2002) |
| "Relapse after treatment of Hodgkin's disease (HD) is usually identified as a result of the investigation of symptoms." | ( Beguin, Y; Belhocine, T; Fassotte, MF; Fillet, G; Hustinx, R; Jerusalem, G; Rigo, P, 2003) |
| "Adult patients (N = 856) with advanced Hodgkin's disease were randomly assigned to treatment with ABVD or MOPP/ABV." | ( Canellos, GP; Connors, JM; Duggan, DB; Fisher, RI; Glick, JH; Johnson, JL; Peterson, BA; Petroni, GR, 2003) |
| "We report on a patient with recurrent Hodgkin's disease, showing this infectious pattern after treatment with corticosteroids within the antineoplastic schedule, whereas neutropenia--the main risk factor for mold infections--had not occurred." | ( Buchheidt, D; Hartung, G; Hehlmann, R; Reiter, S; Weiss, A, 2003) |
| "Extranodal presence of Hodgkin's disease in patients with HIV infection is probably related to immunosuppression, and physicians treating this illness should be alert to the potential of unusual sites of involvement." | ( Kroll, M; Lu, HH; Lynch, GR; Massarweh, S; Sears, DA; Shahab, I; Teh, BS; Udden, MM, 2003) |
| "After three cycles of chemotherapy for Hodgkin's disease, the patient again developed sarcoidosis in the mediastinal lymph nodes." | ( Bronsveld, W; de Graaff, CS; Groeneveld, AB; Ooms, GH; Simsek, S; van Leuven, F, 2002) |
| "Successful treatment of Hodgkin's disease was effective against neurological disturbance." | ( Bernard, P; Flocard, F; Kadouri, A; Talarmin, F; Vinzio, S, 2003) |
| "Treatment strategies in Hodgkin's disease have an impact on different risk factors." | ( Dieckmann, K; Heinzl, H; Hofmann, J; Pötter, R; Schellong, G; Wagner, W, 2003) |
| "A 14-year-old boy treated with Hodgkin's disease developed muscular weakness and pain, hypotonia, abolished deep tendon reflexes." | ( Apjok, E; Magyarosy, E; Marosi, A, 2003) |
| "Our data suggest that: 1) in Hodgkin's disease (67)Ga scintigraphy is useful to establish the diagnosis of complete remission; 2) if the gallium scan remains positive after treatment, the prognosis of patients is worse than the prognosis of patients with a negative scan." | ( Bello, P; Flores, D; Girones, R; González-Cabezas, P; Hervás, I; López-Tendero, P; Mateo, A; Pérez-Velasco, R; Segura, A; Yuste, A, 2003) |
| "Patients had Hodgkin's or non-Hodgkin's lymphoma in chemotherapy-refractory relapse." | ( Abrams, RA; Ambinder, RF; Goodman, S; Haulk, TL; Herman, M; Jones, RJ; Korman, LT; Mann, R; Marcellus, D; Noga, S; Song, DY; Vogelsang, G; Welsh, JS, 2003) |
| "The current management of early stage Hodgkin's disease (HD) is usually based on clinical staging, combined modality therapy and the use of less toxic chemotherapy regimens." | ( Apostolidis, J; Bakiri, M; Baltadakis, J; Grigoriou, E; Harhalakis, N; Karakasis, D; Karmiris, TD; Mihalakeas, H; Mitsouli, C; Nikiforakis, E; Pagoni, M; Spanou, E; Tsantekidou, M, 2003) |
| "Two hundred and fifty-one patients with Hodgkin's disease attending the lymphoma clinic at the Tata Memorial Hospital (Mumbai, India) from 1993 to 1996 received induction chemotherapy with six cycles of ABVD after initial staging evaluation." | ( Dinshaw, KA; Gupta, T; Laskar, S; Muckaden, MA; Naresh, KN; Pai, SK; Saikia, TK; Vimal, S, 2004) |
| "In advanced age the prognosis of Hodgkin's lymphoma (HL) is poor, but, as a consequence of the low incidence of HL in the elderly, prospective studies are lacking and the best treatment strategy is difficult to define." | ( Adamo, F; Ambrosetti, A; Angelucci, E; Anselmo, AP; Bertini, M; Boccadoro, M; Cavalieri, E; Gallo, E; Gavarotti, P; Genua, A; Levis, A; Liberati, M; Mandelli, F; Pavone, V; Pietrasanta, D; Ricetti, MM; Salvi, F; Scalabrini, DR; Vitolo, U, 2004) |
| "Contemporary treatment for pediatric Hodgkin's lymphoma uses a risk-adapted approach that reduces the number of combination chemotherapy cycles and radiation treatment fields and doses for patients with localized favorable disease presentation." | ( Hudson, MM; Kaste, SC; Krasin, MJ, 2004) |
| "Children with Hodgkins disease treated without RT were included in sequential protocols containing six courses of MOPP (n = 24), six courses of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) (n = 17), or three courses of MOPP/ABVD (n = 35)." | ( Behrendt, H; Furstner, F; van den Berg, H; van den Bos, C, 2004) |
| "One hundred patients with Hodgkin's disease (97 with stage I-II disease at presentation) who relapsed after radiation therapy alone were salvaged with either MOPP or ABVD." | ( Fisher, DC; Li, S; Mauch, PM; Neuberg, D; Ng, AK; Silver, B; Stevenson, MA, 2004) |
| "Accurate staging of Hodgkin lymphoma (HD) allows for minimization of therapy and reduction of long-term toxicities." | ( Canellos, GP; Fischman, A; Friedberg, JW; Kim, H; Mauch, PM; Neuberg, D; Ng, AK; Takvorian, T; van den Abbeele, AD, 2004) |
| "One Stage IV patient has died with Hodgkin's disease 28 months after treatment with combination therapy." | ( Bertolone, S; Koerner, P; Oliapuram Jose, B; Paris, KJ; Patel, CC; Silverman, CL; Spanos, WJ; Yashar, CM, 2004) |
| "In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal." | ( Albitar, M; Armitage, JO; Bierman, PJ; Bociek, G; Do, KA; Giles, FJ; Johnson, MM; Kantarjian, HM; Manshouri, T; O'Brien, SM; Vose, JM, 2004) |
| "A 46-year-old woman with Hodgkin's disease who underwent nonmyeloablative allogeneic stem cell transplantation developed cortical blindness, seizures, and left hemiparesis on day 100 while receiving tacrolimus (FK506) and prednisone for the treatment of graft-versus-host disease (GVHD)." | ( Harada, Y; Hatanaka, K; Iio, K; Ikegame, K; Kawakami, M; Kawase, I; Ogawa, H; Oka, Y; Tamaki, H, 2004) |
| "At present, in early stage Hodgkin's disease, 2-6 cycles ABVD followed by decreased dose involved field irradiation is considered to be the standard treatment." | ( Esik, O; Illés, A; Molnár, Z, 2005) |
| "A 33-year-old woman with a diagnosis of Hodgkin's disease had a prechemotherapy whole-body Ga-67 scan to document gallium avidity of lesions and to assess response to therapy." | ( Bazarjani, S; Di Primio, G, 2005) |
| "Primary treatment of advanced Hodgkin's disease." | ( Illés, A; Molnár, Z; Udvardy, M, 2005) |
| "In patients with limited-stage Hodgkin's lymphoma, no difference in overall survival was detected between patients randomly assigned to receive treatment that includes radiation therapy or ABVD alone." | ( Bezjak, A; Burns, BF; Connors, JM; Dar, AR; Ding, K; Djurfeldt, MS; Gospodarowicz, MK; Horning, SJ; Meyer, RM; Pearcey, RG; Shepherd, LE; Wells, WA; Winter, JN, 2005) |
| "Long-term survival from Hodgkin lymphoma (HL) is 80-90%, but the treatment has serious late adverse effects." | ( Fields, PA; Hutchings, M; Mikhaeel, NG; Nunan, T; Timothy, AR, 2005) |
| "Advanced Hodgkin's disease is usually treated with six or more cycles of combination chemotherapy." | ( Bang, SM; Cheong, JW; Hahn, JS; Yang, WI, 2005) |
| "Majority of patients with Hodgkin lymphoma are cured with current therapy." | ( Canellos, GP, 2005) |
| "In patients with Hodgkin's lymphoma (HL) at the end of first line therapy an accurate imaging technique with high prognostic value is needed to assess response to treatment and predict those patients who will suffer disease relapse." | ( Alterini, R; Bernardi, F; Bosi, A; Carpaneto, A; Carrai, V; Castagnoli, A; Dini, C; Matteini, M; Nassi, L; Pieroni, C; Rigacci, L, 2005) |
| "Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results." | ( Ballova, V; Diehl, V; Franklin, J; Glossmann, J; Josting, A; Nogova, L; Rüffer, JU; Sieber, M, 2005) |
| "Patients with refractory Hodgkin's disease or relapsing after high-dose therapy and autografting have a poor prognosis." | ( Aurer, I; Bogdanić, V; Labar, B; Mrsić, M; Nemet, D; Radman, I; Sertić, D; Zupancić-Salek, S, 2005) |
| "Those with limited stage Hodgkin lymphoma should be treated with brief chemotherapy, only augmented with involved field irradiation if an early complete remission is not achieved." | ( Connors, JM, 2005) |
| "Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy and subsequent high dose chemotherapy with autologous stem cell transplantation (ASCT) cannot be cured with conventional treatment." | ( Crump, M; Keating, A; Kuruvilla, J; McCrae, J; Mollee, P; Nagy, T; Panzarella, T; Song, K, 2006) |
| "In early-stage Hodgkin's lymphoma (HL), subtotal nodal irradiation (STNI) and combined chemotherapy/radiotherapy produce high disease control rates but also considerable late toxicity." | ( Aleman, BM; Bosq, J; Carde, P; Dupouy, N; Eghbali, H; Girinsky, T; Hagenbeek, A; Henry-Amar, M; Kluin-Nelemans, JC; Krol, AD; Monconduit, M; Noordijk, EM; Pény, AM; Raemaekers, JM; Thomas, J; Tirelli, U; Verschueren, TA; Vovk, M, 2006) |
| "Currently, 60% patients with advanced Hodgkin's lymphoma could be cured by receiving standard treatments." | ( Fu, XH; Huang, HQ; Huang, Y; Lin, TY; Sun, XF; Wang, B; Wang, SS; Xu, RH; Zhang, L, 2006) |
| "Elderly patients with Hodgkin's lymphoma carry a worse prognosis than younger patients because of a higher incidence of advanced stages, a worse performance status and the intolerance of full-dose curative treatment." | ( Feltl, D; Vítek, P; Zámecník, J, 2006) |
| "We describe a case of Hodgkin lymphoma developing in a 9-year-old girl with polyarticular, rheumatoid factor-positive juvenile idiopathic arthritis treated with methotrexate (MTX), prednisone, and naproxen for 5 years." | ( Abukawa, D; Ichinohazama, R; Imaizumi, M; Nakano, K; Sato, A; Takeyama, J, 2006) |
| "Patients with Hodgkin lymphoma receiving standard ABVD (doxorubicin, bleomycin, vinblastine, and decarbazine) chemotherapy every 14 d were eligible for the study." | ( Fayad, L; Goy, A; Pro, B; Romaguera, J; Wang, M; Younes, A, 2006) |
| "One hundred ten children with low-risk Hodgkin's disease were treated with four cycles of VAMP and 15 Gy IFRT for those who achieved a complete response (CR) or 25." | ( Billett, AL; Brain, S; Donaldson, SS; Hudson, MM; Hurwitz, CA; Krasin, M; Kun, LE; Link, MP; Marcus, KC; Rai, SN; Tarbell, NJ; Weinstein, HJ; Young, JA, 2007) |
| "Pediatric patients with low-risk Hodgkin's disease can be cured with therapy without an alkylating agent, bleomycin, etoposide, or high-dose, extended-field radiotherapy." | ( Billett, AL; Brain, S; Donaldson, SS; Hudson, MM; Hurwitz, CA; Krasin, M; Kun, LE; Link, MP; Marcus, KC; Rai, SN; Tarbell, NJ; Weinstein, HJ; Young, JA, 2007) |
| "Early-stage Hodgkin lymphoma (HL) has excellent survival rates but carries a high risk of late treatment-related adverse effects." | ( Berthelsen, AK; Hansen, M; Hutchings, M; Loft, A; Specht, L, 2007) |
| "The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) aggressive primary treatment should be used even with more severe side effects and complications." | ( Gergely, L; Illés, A; Keresztes, K; Miltényi, Z; Ress, Z; Simon, Z; Vadász, G; Váróczy, L, 2007) |
| "Cure rates of Hodgkin's disease (HD) with chemotherapy and/or radiotherapy are high." | ( Al-Ali, HK; Niederwieser, D; Wittekind, C, 2007) |
| "Patients with early-stage Hodgkin lymphoma treated with combined modality treatments." | ( Bayla, A; Bonniaud, G; Ferreira, I; Ghalibafian, M; Girinsky, T; Lumbroso, J; Magne, N, 2007) |
| "Young adult males surviving Hodgkin's disease, aged 17 and over at least 2 years after therapy were studied in Ali Asghar Children's Hospital, Tehran, Iran from March 2000 to March 2005." | ( Faranoush, M; Hedayatiasl, AA; Rafsanjani, KA; Vossough, P, 2007) |
| "Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure." | ( Baars, JW; Berger, F; Blanc, M; Bosq, J; Brice, P; Carde, P; Carrie, C; Creemers, GJ; Diviné, M; Eghbali, H; Fermé, C; Gabarre, J; Girinsky, T; Gyan, E; Hagenbeek, A; Henry-Amar, M; Jaubert, J; Kluin-Nelemans, JC; Lederlin, P; Lugtenburg, PJ; Meerwaldt, JH; Monconduit, M; Noordijk, EM; Poortmans, P; Raemaekers, JM; Reman, O; Rieux, C; Salles, G; Thomas, J; Tirelli, U; Van den Neste, E; van't Veer, MB; Vié, B; Viseu, F; Walewski, JA, 2007) |
| "The treatment strategies of Hodgkin's lymphoma (HL) are different according to clinical stage and risk factors, yet the optimal treatment strategy remains unclear." | ( Hu, DS; Hu, S; Song, QB; Tan, WY; Wei, L; Zeng, FY; Zhou, LQ, 2007) |
| "Liver involvement in Hodgkin's lymphoma is common and is caused by hepatic infiltration, biliary obstruction by lymphoma, hepatitis, sepsis or complications of chemotherapeutic treatment." | ( de Man, RA; Leeuwenburgh, I; Lugtenburg, EP; van Buuren, HR; Zondervan, PE, 2008) |
| "Due to long-term toxicity of current Hodgkin's lymphoma (HL) treatment, the present challenge is to find new therapies that specifically target deregulated signaling cascades, including NF-kappaB, which are involved in Hodgkin (H) and Reed-Sternberg (RS) cell proliferation and resistance to apoptosis." | ( Adamo, AM; Decker, NP; Mackenzie, GG; Oteiza, PI, 2008) |
| "Although treatment of Hodgkin's lymphoma (HL) with a multi-drug approach has been very successful, its toxicity becomes evident after several years as secondary malignancies and cardiovascular disease." | ( Adamo, AM; Fraga, CG; Mackenzie, GG; Oteiza, PI; Queisser, N; Wolfson, ML, 2008) |
| "Most patients with Hodgkin lymphoma (HL) can be cured with initial multiagent chemotherapy." | ( Oki, Y; Younes, A, 2008) |
| "A 16-year-old Hodgkin lymphoma patient refuses to have his blood specimen drawn, thus canceling his scheduled oncologic treatment." | ( Mulnix, JW, 2008) |
| "Eligible patients had relapsed Hodgkin lymphoma (HL) treated with one or two prior regimens, low grade non-Hodgkin's lymphoma (NHL) treated with one or two prior regimens, or aggressive NHL treated with one prior regimen." | ( Bartlett, NL; Johnson, JL; Peterson, BA; Ratain, MJ; Wagner-Johnston, N, 2009) |
| "Adolescent patients with Hodgkin's lymphoma (HL) are treated either in pediatric, or in adult oncological wards." | ( Csóka, M; Deák, B; Gergely, L; Illés, A; Jakab, Z; Keresztes, K; Kovács, G; Molnár, Z; Müller, J; Rosta, A; Schneider, T; Simon, Z; Várady, E, 2008) |
| "The treatment of Hodgkin's lymphoma has improved dramatically over the past decades." | ( Bar Ad, V; Glatstein, E; Paltiel, O, 2008) |
| "In limited stage Hodgkin lymphoma, early success was obtained with wide field radiotherapy but later combined modality approaches were employed to overcome the problem of out of field radiotherapy relapses." | ( Radford, J, 2008) |
| "Pregnant patients with coincident Hodgkin lymphoma should be staged without the use of imaging requiring radiation and treated with an approach that includes initial treatment deferral when appropriate, single agent vinblastine and reservation of multi-agent chemotherapy for the small minority with very aggressive lymphoma." | ( Connors, JM, 2008) |
| "In 2 relapsed Hodgkin lymphoma patients(131)I-L19SIP radioimmunotherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma therapies." | ( Dürkop, H; Erba, PA; Giovannoni, L; Grana, C; Hirsch, B; Mariani, G; Menrad, A; Menssen, HD; Neri, D; Paganelli, G; Petrini, M; Sauer, S; Zardi, L, 2009) |
| "The end results of treatment of Hodgkin's disease are evaluated." | ( Kuleva, SA, 2008) |
| "Therefore, 126 patients suffering from Hodgkin's disease were investigated after a follow-up of at least 5 years from the completion of the combined treatment." | ( Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Villani, M; Viviani, S, 2009) |
| "Ten percent to 20% of patients with Hodgkin Lymphoma (HL) are refractory to first-line therapy or relapse." | ( Bulusu, R; Camilleri, D; Follows, G; Marcus, R; Raj, S; Stafford, G; Todd, T; Williams, M, 2009) |
| "Current treatment strategies for Hodgkin lymphoma result in excellent survival but often confer significant long-term toxicity." | ( Chauvenet, A; Constine, LS; deAlarcon, PA; Hutchison, RE; Lipshultz, SE; London, WB; Schwartz, CL; Sposto, R; Turner, CS; Villaluna, D, 2009) |
| "In adult Hodgkin's lymphoma (HL) risk stratification after early therapy response assessment with [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) seems to allow tailoring therapy with less toxicity for patients with adequate metabolic response." | ( Amthauer, H; Denecke, T; Furth, C; Hautzel, H; Henze, G; Hundsdoerfer, P; Kobe, C; Misch, D; Ruf, J; Schönberger, S; Steffen, IG; Stöver, B, 2009) |
| "According to the stage of the Hodgkin's disease and the patient's age the modification of the therapy was introduced." | ( Blomannova, E; Dienstbier, Z; Fridrichova, M; Loucka, M; Skala, E, 2009) |
| "In the past few decades Hodgkin lymphoma (HL) has become a highly curable malignant disease, as a result of using modern polychemotherapy and irradiation." | ( Borbényi, Z; Deák, B; Galuska, L; Illés, A; Keresztes, K; Marton, I; Miltényi, Z; Molnár, Z; Rosta, A; Schneider, T; Simon, Z; Trón, L; Várady, E, 2009) |
| "Although classical Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging." | ( Younes, A, 2009) |
| "Limited-stage Hodgkin's lymphoma (HL) has been treated with radiation alone or radiation combined with chemotherapy." | ( Abramson, JS; Canellos, GP; Fisher, DC; LaCasce, AS, 2010) |
| "Accurate staging of Hodgkin's lymphoma (HL) is necessary in selecting appropriate treatment." | ( Anitei, M; Bénamor, M; Brice, P; Brière, J; Cuenca, X; de Kerviler, E; Decaudin, D; Filmont, JE; Hindié, E; Moretti, JL; Moulin-Romsee, G; Sibon, D, 2010) |
| "The majority of patients with advanced Hodgkin's lymphoma are cured with currently available therapy, such as ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine)." | ( Cheson, BD, 2007) |
| "In this study, files of 128 Hodgkin lymphoma patients were reviewed, who were treated in three Hungarian hematology centers between January 1995 and February 2005." | ( Borbenyi, Z; Deak, B; Galuska, L; Illes, A; Keresztes, K; Marton, I; Miltenyi, Z; Molnar, Z; Rosta, A; Schneider, T; Simon, Z; Tron, L; Varady, E, 2010) |
| "Primary treatment for classic Hodgkin lymphoma (HL) remains highly effective with chemotherapy alone or combined-modality therapy." | ( Dougherty, DW; Friedberg, JW, 2010) |
| "Prognostic models for patients with Hodgkin lymphoma are imperfect and do not allow a precise individualized therapy." | ( Diehl, V, 2010) |
| "The majority of patients with Hodgkin lymphoma (HL) achieve disease remission after primary therapy." | ( Aquino, SL; Crowley, D; Feng, Y; Hochberg, EP; Lacasce, AS; Lee, AI; Neuberg, DS; Toomey, C; Van den Abbeele, AD; Zuckerman, DS, 2010) |
| "Fifteen patients with Hodgkin's or non-Hodgkin's lymphoma receiving HD conditioning chemotherapy and autologous SCT were assessed with respect to oral pain and severity of stomatitis on day -6, 0, +5 to +7, +13 to +15, and +100." | ( Cornely, OA; Keulertz, C; Lövenich, H; Rüping, MJ; Söhngen, D; Vehreschild, JJ; Wieland, U, 2011) |
| "One hundred two patients (Hodgkin lymphoma n = 49, non-Hodgkin lymphoma n = 12, multiple myeloma = 41) with a median age of 44 years (range: 19-65 years) were treated." | ( Andersson, BS; Champlin, RE; Hosing, C; Jones, RB; Kazerooni, R; Kebriaei, P; Khouri, I; Ledesma, C; Madden, T; Nieto, Y; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Wang, X, 2011) |
| "In newly diagnosed patients with Hodgkin lymphoma (HL) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD)-related neutropenia on chemotherapy delivery is poorly documented." | ( Culakova, E; Lyman, GH; Pettengell, R; Schwenkglenks, M; Szucs, TD, 2010) |
| "The CTN is involved in trials in Hodgkin's lymphoma [Randomised Phase III trial to determine the role of FDG-PET Imaging in Clinical Stages IA/IIA Hodgkin's Disease (RAPID) and Randomised Phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin lymphoma (RATHL)] and diffuse large B-cell lymphoma [Blinded evaluation of prognostic value of FDG-PET after 2 cycles of chemotherapy in diffuse large B-cell Non-Hodgkins Lymphoma, a sub-study of the R-CHOP-21 vs R-CHOP-14 trial (R-CHOP PET substudy)]." | ( Barrington, SF; Johnson, P; MacKewn, JE; Marsden, PK; Mikhaeel, NG; Mouncey, P; O'Doherty, MJ; Patrick, P; Popova, B; Qian, W; Radford, J; Schleyer, P, 2011) |
| "In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy." | ( Berger, B; Bokemeyer, C; Borchmann, P; Debus, J; Diehl, V; Dörken, B; Eble, MJ; Eich, HT; Engert, A; Fuchs, M; Ganser, A; Greil, R; Ho, A; Kirchner, H; Král, Z; Lohri, A; Müller, RP; Müller-Hermelink, HK; Plütschow, A; Rank, A; Schubert, J; Sökler, M; Trümper, L; Wilhelm, M; Willborn, KC, 2010) |
| "We identified the diagnosis of non-Hodgkin's lymphoma and previous radiotherapy as independent factors that contributed to failure of mobilization." | ( Basak, GW; Dabrowska-Iwanicka, A; Dybko, J; Hawrylecka, D; Kisiel, E; Knopinska-Posluszny, W; Matuszak, M; Rzepecki, P; Szmigielska-Kaplon, A; Urbaniak-Kujda, D; Werkun, J; Wiktor-Jedrzejczak, W; Wroblewska, W; Zielinska, P, 2011) |
| "The majority of patients with Hodgkin's disease can be cured by combination of polychemotherapy and radiotherapy (RT) that can produce late toxic pulmonary and cardiac effects which often remain at a subclinical level." | ( Bonfante, V; Busia, A; Laffranchi, A; Villani, F; Viviani, S, 2010) |
| "Approximately 80% of Hodgkin's lymphoma (HL) patients achieve long-term remission after primary chemotherapy or chemo/radiotherapy." | ( Borchmann, P; Eichenauer, DA; Engert, A; Fuchs, M, 2008) |
| "Allo-HCT in heavily pretreated relapsed Hodgkin lymphoma is feasible, tolerable, and can induce durable clinical remissions." | ( Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E, 2011) |
| "Around 20% of Hodgkin lymphoma (HL) patients are refractory to first-line therapy with ABVD (adriamycin-bleomycin-vinblastine-dacarbazine) or relapse after complete remission." | ( Al Nawakil, C; Beranger, N; Brice, P; Brière, J; de Bazelaire, C; de Kerviler, E; Ertault, M; Franchi, P; Sibon, D; Thieblemont, C, 2011) |
| "All but 2 patients had early-stage Hodgkin lymphoma, and they were treated with chemotherapy prior to irradiation." | ( Beaudre, A; Ferreira, I; Ghalibafian, M; Girinsky, T; Lefkopoulos, D; Lessard, NA; Messai, T; Paumier, A; Pichenot, C, 2011) |
| "Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients with relapsed or refractory disease remains challenging and novel agents are under development." | ( Artells, R; Bellosillo, B; Diaz, T; Ferrer, G; Garcia-Garcia, M; Gaya, A; Gel, B; Martínez, A; Monzo, M; Navarro, A; Serrano, S, 2011) |
| "Although patients with Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy frequently develop neutropenia, febrile neutropenia is uncommon." | ( Bhagirath, V; Chin-Yee, BH; Chin-Yee, IH; Lazo-Langner, A; Mangel, JE; Minuk, LA; Monkman, K, 2012) |
| "A 35-year-old male with classical Hodgkin's lymphoma (nodular sclerosing, grade 1 histology, clinical stage 2A) underwent a positron emission tomography (PET) scan to assess response to treatment." | ( Dyer, MJ; Entwisle, J; Harman, KE; Simpson, RC, 2011) |
| "Fifty-three Hodgkin lymphoma patients with a median age of 14 years (6-21 years) underwent multiagent chemotherapy followed by involved field radiotherapy (IFRT) to initial sites of disease." | ( Chiang, S; Dreyer, Z; Margolin, J; Paulino, AC; Teh, BS, 2012) |
| "In contrast to classical Hodgkin lymphoma (CHL), chemotherapy is often omitted; however, it is unknown whether this impacts the risk of relapse." | ( Al-Mansour, M; Connors, JM; Gascoyne, RD; Savage, KJ; Sehn, LH; Skinnider, B, 2011) |
| "Accurate staging of classical Hodgkin lymphoma (CHL) directs treatment intensity." | ( McNamara, CJ; Ramsay, A; Richardson, SE; Sudak, J; Warbey, V, 2012) |
| "Approximately 20% of all Hodgkin lymphoma (HL) patients are older than 60 years and have a poor prognosis, mainly because of increased treatment-related toxicity resulting in reduced overall dose intensity and more treatment-related mortality." | ( Böll, B; Borchmann, P; Bredenfeld, H; Eich, HT; Eichenauer, DA; Engert, A; Fuchs, M; Geissler, M; Görgen, H; Graeven, U; Halbsguth, T; Keller, U; Kremers, S; Markova, J; Soekler, M; Trenn, G; von Tresckow, B, 2011) |
| "Although most of the patients with Hodgkin's lymphoma (HL) can be cured by the current regimen of high-dose multiagent chemotherapy, the treatment causes high risks of later toxicities including secondary malignancies." | ( Fulda, S; Giaisi, M; Köhler, R; Krammer, PH; Li-Weber, M, 2012) |
| "Therapy of Hodgkin lymphoma (HL) is designed to prolong survival and minimize toxicity." | ( Avivi, I; Bar-Shalom, R; Ben-Shachar, M; Blumenfeld, Z; Dann, EJ; Epelbaum, R; Gaitini, D; Goor, O; Libster, D; Rowe, JM, 2012) |
| "The paediatric Hodgkin lymphoma treatment optimisation concepts aim at reduction of treatment intensity with preservation of the high cure rates." | ( Kluge, R; Körholz, D, 2011) |
| "Treatment options for relapsing Hodgkin lymphoma (HL) are controversial after autologous hemopoietic stem cell transplantation (HSCT)." | ( Barna, S; Illés, Á; Magyari, F; Simon, Z; Udvardy, M; Váróczy, L, 2012) |
| "The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells." | ( Rezvani, K, 2011) |
| "Among patients with Hodgkin's lymphoma, ABVD therapy alone, as compared with treatment that included subtotal nodal radiation therapy, was associated with a higher rate of overall survival owing to a lower rate of death from other causes." | ( Chen, BE; Connors, JM; Crump, M; Dar, AR; Djurfeldt, MS; Gospodarowicz, MK; Horning, SJ; Meyer, RM; Pearcey, RG; Shepherd, LE; Shustik, C; Stewart, DA; Wells, WA; Winter, JN, 2012) |
| "In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in long-term tumor control of approximately 80%." | ( Borchmann, P; Diehl, V; Eich, HT; Engert, A; Fuchs, M; Greil, R; Klimm, B; Kral, Z; Lohri, A; Markova, J; Meissner, J; Mueller, RP; Plütschow, A; Soekler, M; Stein, H; Topp, MS; von Tresckow, B; Zijlstra, JM, 2012) |
| "Investigating 30 patients with non-Hodgkin's lymphoma, one patient with Hodgkin's lymphoma, and five patients with multiple myeloma, we compared the effects of several doses of etoposide with those of CHOP or CHOP-like treatments or salvage treatments." | ( Asaka, M; Imamura, M; Ito, S; Morita, A; Murata, N; Ogasawara, R; Sasaki, J; Senoo, N; Tanaka, J; Tsutsumi, Y, 2012) |
| "In patients with early-stage Hodgkin lymphoma and a favorable prognosis, treatment with two cycles of aBVD followed by 20 Gy of involved-field radiation therapy was as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy." | ( Anter, AH; Awad, IA; Hamed, RH, 2012) |
| "The treatment results of 296 Hodgkin's disease patients receiving ABVD or BEACOPP-21 chemotherapy with consequent EFRT demonstrate CR/PR > or = 80% and 99% local disease control rate." | ( Datsenko, PV; Evstikheev, ÉV; Golub, SV; Gombolevskiĭ, VA; Ivashin, AV; Pan'shin, GA; Sotnikov, VM, 2012) |
| "Among patients with favorable-risk Hodgkin lymphoma and a complete early response to chemotherapy, the use of limited radiotherapy resulted in a high rate of 2-year event-free survival." | ( Billett, AL; Billups, CA; Donaldson, SS; Friedmann, A; Howard, SC; Hudson, MM; Krasin, MJ; Kun, LE; Larsen, EC; Link, MP; Marcus, KJ; Metzger, ML; Tarbell, N; Weinstein, HJ; Wu, J; Yock, TI, 2012) |
| "Thirty-one children with Hodgkin lymphoma underwent whole-body T2-weighted MRI with supplementary DCE splenic imaging, and whole-body PET-CT before and following chemotherapy." | ( Bainbridge, A; Bell, N; Ben-Haim, S; Cheung, KK; Daw, S; Groves, AM; Hain, SF; Halligan, S; Humphries, PD; Punwani, S; Shankar, A; Skipper, N; Taylor, SA, 2013) |
| "A cohort of advanced-stage Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) were enrolled retrospectively from centers worldwide." | ( Barrington, SF; Biggi, A; Chauvie, S; Gallamini, A; Gregianin, M; Hofman, MS; Hutchings, M; Kostakoglu, L; Malkowski, B; Meignan, M, 2013) |
| "Based on the treatment results of 300 Hodgkin lymphoma patients the authors formulated the basic approaches for radiation treatment in ABVD and BEACOPP-21 chemotherapy regimens recipients." | ( Datsenko, PV; Evstikheev, ÉV; Golub, SV; Gombolevskiĭ, VA; Ivashin, AV; Pan'shin, GA; Sotnikov, VM, 2012) |
| "The incidence of Hodgkin lymphoma (HL) has increased since introduction of combined antiretroviral therapy (cART)." | ( Amiran, ES; Chiao, EY; Kowalkowski, MA; Lulla, P; Mims, MP, 2013) |
| "We present the case of Hodgkin's lymphoma in a 51 years old female, who presented with obstructive jaundice and lymphadenopathy, empirically treated previously as a case of tuberculosis." | ( Abbasi, NZ; Ali, F; Jalal-ud-Din, M; Khan, AA; Memon, KH; Sheikh, AS; Zahur, Z, 2013) |
| "The key question in advanced-stage Hodgkin lymphoma for many years now has been, should intensified chemotherapy be applied upfront or be reserved for relapsing patients." | ( Borchmann, P, 2014) |
| "For relapsed-refractory Hodgkin Lymphoma, standard therapy consists of salvage chemotherapy followed by autologous stem cell transplantation." | ( Hertzberg, M, 2014) |
| "Although Hodgkin's lymphoma (HL) was one of the first human cancers to be cured by chemotherapy, no new agents other than brentuximab vedotin (Adcetris®, CD 30 directed antibody drug conjugate) have received US Food and Drug Administration (FDA) approval for HL since 1977." | ( Brown, RE; Buryanek, J; Hong, D; Janku, F; McGuire, MF; Subbiah, V; Younes, A, 2014) |
| "Most patients with Hodgkin lymphoma (HL) are cured with modern combined modality first-line treatments." | ( Diehl, V; von Tresckow, B, 2014) |
| "Limited-stage Hodgkin lymphoma can almost always be cured with combined-modality chemotherapy plus involved-field or involved-nodal radiation, at the cost of exposing all patients--many unnecessarily--to radiation." | ( Connors, JM, 2014) |
| "The majority of patients with advanced Hodgkin lymphoma are cured with current standard therapy such as Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD)." | ( Cheson, BD, 2014) |
| "The standard treatment of early-stage Hodgkin lymphoma (ESHL) as recommended by most national guidelines is combined modality treatment (CMT) that includes a short course ABVD followed by a small field of low dose radiotherapy (RT)." | ( Yahalom, J, 2014) |
| "Long-term Hodgkin lymphoma (HL) survivors have an increased risk of late cardiac morbidity and secondary lung cancer after chemotherapy and mediastinal radiotherapy." | ( Andersen, FL; Aznar, MC; Berthelsen, AK; Josipovic, M; Klausen, TL; Loft, A; Maraldo, M; Petersen, PM; Schut, DA; Specht, L, 2015) |
| "Modern treatment of Hodgkin's lymphoma (HL) has transformed its prognosis but causes late effects, including premature menopause." | ( Bates, A; Cooke, R; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Linch, DC; Lister, A; Lucraft, HH; Radford, J; Stevens, AM; Swerdlow, AJ; Syndikus, I; Williams, MV, 2014) |
| "48 patients with de novo Hodgkin lymphoma were treated with 2 cycles of chemotherapy." | ( Blasco, H; Colombat, P; Eder, V; Iltis, A; Sénécal, D, 2015) |
| "402 patients with Hodgkin lymphoma were treated using the BEACOPP-14 protocol in 2006 to 2013." | ( Al'-Radi, LS; Iatsyk, GA; Khlavno, AB; Kravchenko, SK; Margolin, OV; Moiseeva, TN; Shitareva, IV, 2014) |
| "We herein present a case of Hodgkin lymphoma associated with HLH in which the HLH did not improve even after chemotherapy." | ( Fujiwara, S; Muroi, K; Nagai, T; Oh, I; Ozawa, K; Sato, M; Tatara, R, 2014) |
| "HIV-associated classical Hodgkin lymphoma (HIV-cHL) is an important complication of HIV disease in the era of effective combination antiretroviral therapy (cART)." | ( Little, RF; Uldrick, TS, 2015) |
| "He was diagnosed with Hodgkin's lymphoma and initiated on treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine." | ( Hughes, CL; Kovitz, C; Oki, Y; Yorio, JT, 2014) |
| "Therapy for Hodgkin lymphoma (HL) is associated with excellent long-term survival rates, of 80% of more." | ( Johnson, PW; Remer, M, 2015) |
| "The cure rate in Hodgkin lymphoma is high, but the response along with treatment is still unpredictable and highly variable among patients." | ( Alarcón, C; Alonso, JM; Chamorro, C; deAndrés-Galiana, EJ; Del Coz, JJ; Fernández, R; Fernández-Martínez, JL; Gonzalez, S; González-Ordóñez, A; González-Rodríguez, AP; Luaces, O; Medina, J; Morán, M; Nogués, EA; Ortiz, S; Palicio, MA; Payer, AR; Solano, J; Taboada, F; Vargas, M; Vicente, JM; Zanabilli, Y, 2015) |
| "Adaptation of patients with Hodgkin's lymphoma can take place only after successful treatment, the probability of relapse and fear of repeated courses strongly interfere with this process, especially in the first years after its closure." | ( Datsenko, PV; Panshin, GA, 2015) |
| "When evaluating response of Hodgkin lymphoma (HL) to chemotherapy on interim (18)F-FDG-PET/CT, physiological liver uptake is used as reference." | ( Bordenave, L; Colletti, PM; Gordien, P; Guyot, M; Hindié, E; Morliere, C; Rubello, D, 2015) |
| "We report a case with refractory Hodgkin lymphoma treated with haploidentical PBSC transplantation with nonmyeloablative conditioning and pT-HDCy." | ( Chen, RL; Chen, WT; Fang, LH; Liu, WH, 2015) |
| "He was diagnosed with stage II Hodgkin's lymphoma at the age of 15, and we considered the possibility of newly emerged CNS lymphoma occurring in the immunosuppressive condition after the treatment of Hodgkin's lymphoma." | ( Hirose, S; Mashima, K; Mori, T; Okamoto, S; Shimizu, T; Suzuki, N; Suzuki, S; Yamada, S, 2015) |
| "For relapsed/refractory Hodgkin lymphoma patients novel treatment options may offer better chance for cure." | ( Illés, Á; Jóna, Á; Miltényi, Z; Simon, Z; Udvardy, M, 2015) |
| "The disease relapse rate in Hodgkin lymphoma patients with a FDG-PET-negative residual mass after first-line therapy is approximately 6." | ( Adams, HJ; Kwee, TC; Nievelstein, RA, 2015) |
| "To evaluate, in children with Hodgkin lymphoma (HL), the frequency and intensity of visually diffuse FDG uptake by selected organs at baseline (bPET) and on interim PET/CT (iPET), and to evaluate the relation between FDG uptake, metabolic response and evolution of the disease with treatment." | ( Abbou, S; Balogova, S; Ducou-Lepointe, H; Jorgov, L; Landman-Parker, J; Leblanc, T; Montravers, F; Pacquement, H; Ragu, C; Talbot, JN, 2016) |
| "Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT)." | ( Alram, M; Borchmann, P; Doehner, H; Engert, A; Fischer, T; Metzner, B; Müller, H; Niederwieser, DW; Raemaekers, JM; Sasse, S; Schäfer-Eckart, K; Schmalz, O; Schmitz, N; Smardová, L; Tresckow, BV, 2016) |
| "In advanced Hodgkin lymphoma (HL), RT to residual disease and/or initial bulk benefits some patients, depending on the chemotherapy regimen used." | ( Specht, L, 2016) |
| "Despite relative success of therapy for Hodgkin's lymphoma (HL), novel therapeutic agents are needed for patients with refractory or relapsed disease." | ( Bamford, RN; Ferrer, M; Guha, R; Ju, W; Petrus, MN; Thomas, CJ; Waldmann, TA; Wilson, KM; Zhang, M; Zhang, X, 2016) |
| "The study initially enrolled Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients ages 18 to 80 years but was amended due to high early treatment-related mortality (TRM) in patients > 65 years." | ( Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF, 2016) |
| "Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT)." | ( Aurer, I; Bašić-Kinda, S; Dotlić, S; Dujmović, D; Kralik, M; Labar, B; Mazić, S; Mitrović, Z; Nemet, D; Radman, I; Šantek, F; Sertić, D, 2016) |
| "Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies." | ( Batlevi, CL; Bociek, RG; Buglio, D; Copeland, A; Cruickshank, S; Gore, L; Hernandez-Ilizaliturri, F; Kasamon, Y; Kunkel, L; Lee, P; Ordentlich, P; Sorensen, R; Younes, A, 2016) |
| "Two patients with Hodgkin's lymphoma and two with non-Hodgkin's lymphoma who were undergoing stem cell therapy were studied." | ( Arima, N; Fukunaga, A; Hyuga, M; Iwasaki, M; Kishimoto, W; Maesako, Y; Nakae, Y, 2016) |
| "As current classical Hodgkin lymphoma (cHL) treatment strategies have pronounced side-effects, specific inhibition of signaling pathways may offer novel strategies in cHL therapy." | ( Birkenmeier, K; Dröse, S; Hansmann, ML; Hartmann, S; Moll, K; Newrzela, S, 2016) |
| "We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to Dec 31, 2012." | ( Agati, P; Agostinelli, C; Argnani, L; Biggi, A; Borra, A; Broccoli, A; d'Amore, F; Fanti, S; Fuligni, F; Gallamini, A; Gascoyne, RD; Hamilton-Dutoit, S; Kamper, P; Kulikowski, W; Levis, A; Małkowski, B; Merli, F; Patti, C; Piccaluga, PP; Pileri, SA; Rigacci, L; Romano, A; Rybka, J; Sista, MT; Steidl, C; Stelitano, C; Stracqualursi, L; Subocz, E; Tajer, J; Trentin, L; Tripodo, C; Vitolo, U; Zaucha, JM; Zinzani, PL, 2016) |
| "Treating Hodgkin lymphoma by using chemotherapy with or without radiotherapy is highly successful, with substantially fewer deaths from lymphoma than from other causes in recent studies of both early-stage and advanced-stage disease." | ( Johnson, PW, 2016) |
| "Classical Hodgkin lymphoma is a relatively uncommon etiology of hemophagocytic lymphohistiocytosis and may complicate treatment options." | ( Bansal, P; Dayao, Z; Hu, S; Lynch, D; Rojas Hernandez, CM, 2016) |
| "Although Hodgkin lymphoma (HL) is curable with current therapy, at least 20% of patients relapse or fail to make complete remission." | ( Ascione, B; Careddu, G; Carlo-Stella, C; Ciarlo, L; Locatelli, SL; Malorni, W; Maselli, A; Matarrese, P; Ortona, E; Patrizio, M; Pierdominici, M; Tinari, A, 2017) |
| "In early-stage classical Hodgkin lymphoma, fluorodeoxyglucose positron emission tomography (PET)-computed tomography (CT) scans are performed routinely after chemotherapy, and the 5-point Deauville score is used to report the disease response." | ( Akhtari, M; Chuang, H; Dabaja, BS; Dong, W; Fanale, M; Garg, N; Gunther, JR; Khoury, JD; Mawlawi, O; Milgrom, SA; Oki, Y; Osborne, EM; Pinnix, CC; Reddy, JP; Rohren, E; Smith, GL; Suki, T; Yehia, ZA, 2017) |
| "Patients treated for stage I to II Hodgkin lymphoma from 2003 to 2013, who were aged ≥18 years and had analyzable PET-CT scans performed before and after chemotherapy, were eligible." | ( Akhtari, M; Chuang, H; Dabaja, BS; Dong, W; Fanale, M; Garg, N; Gunther, JR; Khoury, JD; Mawlawi, O; Milgrom, SA; Oki, Y; Osborne, EM; Pinnix, CC; Reddy, JP; Rohren, E; Smith, GL; Suki, T; Yehia, ZA, 2017) |
| "Therefore, Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy and/or high-dose procarbazine could benefit from colonoscopy, or other surveillance modalities, which are expected to reduce colorectal cancer incidence and mortality." | ( Aleman, BM; Bisseling, TM; Bleiker, EM; Carvalho, B; Cats, A; de Boer, JP; Janus, CP; Jóźwiak, K; Lansdorp-Vogelaar, I; Lugtenburg, PJ; Meijer, GA; Moons, LM; Petersen, EJ; Raemaekers, JM; Rigter, LS; Roesink, JM; Snaebjornsson, P; Spaander, MC; Te Riele, H; van der Maazen, RW; van Leerdam, ME; van Leeuwen, FE, 2017) |
| "Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown." | ( Cheah, CY; Dabaja, B; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Horowitz, SB; Lai, CM; Lee, HJ; McLaughlin, P; Medeiros, LJ; Milgrom, SA; Nastoupil, L; Neelapu, SS; Oki, Y; Pinnix, CC; Rich, A; Rodriguez, MA; Romaguera, JE; Samaniego, F; Turturro, F; Wang, ML; Westin, JR; Younes, A, 2017) |
| "For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down." | ( Anglaret, B; Audhuy, B; Bologna, S; Bouabdallah, R; Brice, P; Brière, J; Carde, P; Casasnovas, O; de Jong, D; de Weerdt, O; Delarue, R; Eghbali, H; Fermé, C; Henry-Amar, M; Janvier, M; Lugtenburg, PJ; Lybeert, MLM; Marjanovic, Z; Noordijk, EM; Raemaekers, JMM; Reman, O; Salles, G; Sebban, C; Spina, M; Tersteeg, RJHA; Thomas, J; Thyss, A; van Imhoff, GW; Vranovsky, A, 2017) |
| "Early-stage classical Hodgkin lymphoma (HL) patients are evaluated by an end-of-chemotherapy positron emission tomography-computed tomography (eoc-PET-CT) after doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and before radiation therapy (RT)." | ( Abou Yehia, Z; Akhtari, M; Chuang, H; Dabaja, BS; Dong, W; Fanale, M; Fayad, LE; Garg, N; Gunther, JR; Hagemeister, FB; Lee, HJ; Mawlawi, O; Milgrom, SA; Oki, Y; Osborne, EM; Pinnix, CC; Reddy, JP; Rohren, E; Smith, GL, 2017) |
| "Classic Hodgkin lymphoma patients seldom received tumor resection surgery, but for the special bone classic Hodgkin lymphoma individual with a huge tumor volume and high risk of pathological fracture in our study, limb-salvage surgery based on ABVD chemotherapy provided a satisfying clinical outcome." | ( Min, L; Tang, B; Tang, F; Tu, C; Ye, Y; Zhang, W; Zhou, Y, 2017) |
| "The presence of bulky disease in Hodgkin lymphoma (HL), traditionally defined with a 1-dimensional measurement, can change a patient's risk grouping and thus the treatment approach." | ( Abou Yehia, Z; Akhtari, M; Andraos, TY; Chuang, H; Dabaja, BS; Dong, W; Fanale, M; Garg, N; Gunther, J; Khoury, JD; Mawlawi, O; Milgrom, SA; Oki, Y; Osborne, EM; Pinnix, CC; Reddy, JP; Rohren, E; Smith, GL; Wogan, CF, 2018) |
| "While patients with early-stage Hodgkin lymphoma (HL) have an excellent outcome with combined treatment, the radiation therapy (RT) dose and treatment with chemotherapy alone remain questionable." | ( Aleman, BMP; André, M; Audouin, J; Beijert, M; Bordessoule, D; Bouabdallah, K; Boulat, O; Christian, B; de Jong, D; Eghbali, H; Fermé, C; Gabarre, J; Gaillard, I; Girinsky, T; Gonzalez, H; Hélias, P; Henry-Amar, M; Jaubert, J; Lugtenburg, PJ; Lybeert, MLM; Morschhauser, F; Noordijk, EM; Ong, F; Quittet, P; Roesink, JM; Stamatoullas, A; Tertian, G; Thomas, J; Tirelli, U; van der Maazen, RWM; Vranovsky, A, 2018) |
| "Several pediatric Hodgkin lymphoma (HL) consortia have demonstrated safe omission of radiotherapy (RT) in early stage HL, whereas feasibility of omitting RT in advanced HL is still under investigation." | ( Billett, AL; LaCasce, AS; Marcus, KJ; Ozuah, NW, 2018) |
| "Herein synchronous occurrence of Hodgkin lymphoma and secondary myelodysplastic syndrome in a 60 year old male patient with small cell lung cancer treated with combined chemotherapy (carboplatin and paclitaxel) and radiotherapy is presented." | ( Mladenovska, K; Petrusevska, M; Petrushevska, G; Stavridis, IP, 2017) |
| "The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10-15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed." | ( Carella, AM; Corradini, P; Mussetti, A; Ricardi, U; Vitolo, U; Viviani, S, 2018) |
| "Particularly in Hodgkin lymphoma, positive interim FDG-PET/CT scans are adversely prognostic for clinical outcomes and can inform PET-adapted treatment strategies, but such data are less consistent in diffuse large B-cell lymphoma." | ( Baech, J; Cheah, CY; El-Galaly, TC; Gormsen, LC; Lo, A; Villa, D, 2018) |
| "Our analysis set consisted of 832 Hodgkin lymphoma patients from the German Hodgkin Study Group trials HD16, HD17, and HD18 who underwent both PET scanning and BM biopsy before treatment." | ( Baues, C; Borchmann, P; Dietlein, M; Drzezga, A; Engert, A; Fuchs, M; Goergen, H; Klaeser, B; Kobe, C; Kreissl, S; Mettler, J; Moccia, A; Oertl, J; Voltin, CA, 2018) |
| "A 15-year-old girl with Hodgkin lymphoma in the neck underwent follow-up FDG PET/CT scan to monitor the response to the chemotherapy." | ( Bai, X; Wang, X, 2018) |
| "Patients with relapsed or refractory Hodgkin's lymphoma are likely incurable with standard treatment." | ( Baillet, C; Barbieux, S; Boyle, EM; Demarquette, H; Herbaux, C; Morschhauser, F; Vermersch, P, 2018) |
| "Women treated with chest radiation for Hodgkin lymphoma (HL) have significantly higher risk of developing breast cancer, and little is known about how these patients tolerate chemotherapy for breast cancer." | ( Baxstrom, K; Blaes, A; Lee, C; Peterson, B; Turcotte, L; Vogel, R; Watson, AP, 2018) |
| "Women treated for Hodgkin lymphoma (HL) with chest radiation have significantly higher risk of developing breast cancer, and little is known about how these patients tolerate chemotherapy for breast cancer." | ( Baxstrom, K; Blaes, A; Lee, C; Peterson, B; Turcotte, L; Vogel, R; Watson, AP, 2018) |
| "Because continuous chemotherapy for Hodgkin's lymphoma was needed, he continued valacyclovir as secondary prophylaxis for 6 months and he accomplished the chemotherapy without contralateral progression." | ( Kageyama, Y; Kawakami, K; Nagaharu, K; Yamaguchi, T, 2017) |
| "Use of FDG-PET to guide treatment in Hodgkin lymphoma has been recommended." | ( Bair, SM; Svoboda, J, 2019) |
| "Reporting the first case of localized Hodgkin lymphoma treated with protontherapy in France." | ( Abbassi, LM; Arsène-Henry, A; Dendale, R; Goudjil, F; Kirova, YM, 2019) |
| "Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)-adapted therapy on SWOG S0816." | ( Barr, PM; Bartlett, NL; Evens, AM; Friedberg, JW; Hsi, ED; Kahl, BS; Knopp, MV; LaCasce, AS; LeBlanc, M; Leonard, JP; Li, H; Moskowitz, CH; Rimsza, LM; Schöder, H; Smith, SM; Stephens, DM; Straus, DJ, 2019) |
| "To assess the results of Hodgkin lymphoma treatment using the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen." | ( Cabrera C, ME; Puga L, B; Salinas, M; Torres, V, 2019) |
| "Treatment options for Hodgkin's Lymphoma differ among various study groups and there is still no consensus regarding the standard treatment for Hodgkin's lymphoma." | ( Asad, M; Mehreen, A; Ria, S; Sindhu, II; Wali, RM, 2019) |
| "One-in-five Hodgkin Lymphoma (HL) patients treated with bleomycin develop bleomycin pulmonary toxicity (BPT)." | ( Ansell, SM; Habermann, TM; Liu, H; Polley, MY; Ristow, K; Taparra, K, 2020) |
| "When treating limited stage classical Hodgkin lymphoma (cHL), balancing treatment efficacy and toxicity is important." | ( Åkesson, L; Björkholm, M; Enblad, G; Erlanson, M; Fluge, Ø; Fohlin, H; Fosså, A; Glimelius, B; Glimelius, I; Goldkuhl, C; Gustavsson, A; Holte, H; Johansson, AS; Lagerlöf, I; Linderoth, J; Molin, D; Nome, O; Palma, M; Raud, C; Østenstad, B, 2020) |
| "Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is unlikely to regress following discontinuation of MTX, and its treatment usually requires chemotherapy." | ( Fujii, H; Fukuhara, N; Harigae, H; Ichikawa, S; Ichinohasama, R; Onishi, Y; Onodera, K; Saito, K; Shirai, T; Yokoyama, H, 2020) |
| "Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated." | ( Altuntaş, F; Bakırtaş, M; Başçı, S; Batgi, H; Dal, MS; Darçın, T; İskender, D; Kızıl Çakar, M; Merdin, A; Şahin, D; Tetik, A; Uncu Ulu, B; Yiğenoğlu, TN; Yıldız, J, 2020) |
| "Elderly Hodgkin lymphoma (HL) is an aggressive lymphoma subgroup with high 18F-FDG avidity at 18F-FDG-PET/CT but no shared criteria for PET/CT in treatment evaluation and prediction of outcome are available." | ( Albano, D; Bertagna, F; Giubbini, R; Mazzoletti, A; Muzi, C; Pagani, C; Rossetti, C; Spallino, M; Tucci, A; Zilioli, VR, 2020) |
| "In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects." | ( Baues, C; Borchmann, P; Bormann, M; Bröckelmann, PJ; Engert, A; Fuchs, M; Goergen, H; Halbsguth, TV; Hüttmann, A; Keller, U; Kerkhoff, A; Klapper, W; Kobe, C; Mathas, S; Meissner, J; Mettler, J; Ordemann, R; Rosenwald, A; Sasse, S; Sökler, M; von Tresckow, B; Zimmermann, A, 2020) |
| "SWOG-S0816 treated advanced stage Hodgkin lymphoma patients with ABVD+/- escBEACOPP and no RT." | ( Bartlett, NL; Constine, LS; Evens, AM; Friedberg, JW; Ha, CS; Hsi, ED; Kahl, BS; Knopp, MV; LeBlanc, M; Leonard, JP; Li, H; Pinnix, CC; Rimsza, L; Schöder, H; Smith, S; Zhang, J, 2020) |
| "Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment-related complications." | ( Ansell, SM; Budde, LE; Deal, AM; Ghosh, N; Noe, JF; Olajide, O; Park, SI; Reddy, NM; Shea, TC, 2020) |
| "Objective Classic Hodgkin lymphoma (CHL) has been regarded as a curable disease when treated appropriately, especially in younger patients, and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been regarded as the standard regimen." | ( Chiwata, M; Fujioka, M; Imaizumi, Y; Kitanosono, H; Makiyama, J; Miyazaki, Y; Nakashima, J; Watanabe, H; Yoshida, S, 2021) |
| "Nine Hodgkin lymphoma (HL) patients provided 20 semen samples before, during, and after NOVP therapy (Novantrone, Oncovin, Velban and Prednisone) and radiation therapy that produced scattered gonadal doses from <0." | ( Frias, S; Meistrich, ML; Van Hummelen, P; Wyrobek, AJ, 2020) |
| "Although classic Hodgkin's lymphoma (CHL) sometimes develops after treatment for multiple myeloma (MM), simultaneous diagnosis of both malignancies is extremely rare without previous treatment history." | ( Andoh, S; Imai, Y; Kawamata, T; Makiyama, J; Ota, Y; Tojo, A; Uchida, S; Yasui, H; Yokoyama, K, 2021) |
| "Treatment differs from classical Hodgkin lymphoma in some situations." | ( Eichenauer, DA; Engert, A, 2021) |
| "As most patients with classical Hodgkin lymphoma will relapse during or after this treatment, clinicians often provide consolidation with allogeneic hematopoietic cell transplantation (alloHCT) in fit patients." | ( Bosch Vilaseca, A; Domingo-Domenech, E; Mussetti, A; Parody, R; Paviglianiti, A; Sureda, AM, 2021) |
| "Non-Hodgkin or Hodgkin lymphoma patients (n = 122) between 15 and 35 years old were prospectively recruited before commencing chemotherapy." | ( Barbatti, M; Behal, H; Bruno, B; Decanter, C; Delepine, J; Labreuche, J; Manier, S; Morschhauser, F; Pigny, P; Robin, C, 2021) |
| "Total 154 pediatric Hodgkin lymphoma (HL) survivors uniformly treated with ABVD were clinically followed up as per institutional protocol." | ( Bakhshi, S; Bhethanabhotla, S; Biswas, A; Ganguly, S; Khadgawat, R; Mittal, A; Mohan, A; Patel, C; Vishnubhatla, S, 2021) |
| "Patients with classical Hodgkin lymphoma (cHL) who do not achieve complete remission (CR) after second-line chemotherapy have poor clinical outcomes." | ( Cai, J; Cai, QQ; Huang, H; Huang, HQ; Li, ZM; Liu, PP; Ma, SY; Su, N; Wang, JN; Xia, Y; Xia, ZJ; Zhang, YC, 2022) |
| "Pre-treatment PET scans from 60 Hodgkin lymphoma patients from the EuroNet-PHL-C1 trial were evaluated." | ( Georgi, TW; Kluge, R; Körholz, D; Kornrumpf, K; Kurch, L; Mauz-Körholz, C; Posch, S; Sabri, O; Zieschank, A, 2022) |
| "A 60-year-old woman with relapsed Hodgkin's lymphoma developed nausea and fatigue after receiving penpulimab monotherapy (200 mg every 2 weeks)." | ( Han, J; Li, Y; Tao, Y, 2022) |
| "Chemotherapy for classic Hodgkin lymphoma (cHL) patients on hemodialysis (HD) is an extremely challenging situation because pharmacokinetic and pharmacodynamic studies of most chemotherapeutics are lacking for the HD patient, and the small amount of evidence available comes mostly from case reports and small case series." | ( Ando, J; Ando, M; Komatsu, N; Yasuda, H, 2022) |
| "The standard of care for early-stage Hodgkin Lymphoma (HL) is combined modality therapy (CMT) consisting of chemotherapy and involved site radiation therapy (ISRT)." | ( Adefres, B; Chang, EM; Huang, TQ; Parikh, N; Raldow, A; Smith, CP, 2022) |
| "Patients with classical Hodgkin lymphoma (cHL) relapsing after second-line therapy have a dismal prognosis and novel approaches are required for this patient group." | ( Böll, B; Borchmann, P; Borchmann, S; Bröckelmann, PJ; Eichenauer, DA; Engert, A; Fuchs, M; Gillessen, S; Heger, JM; Kobe, C; Ostermann, H; Pluetschow, A; von Tresckow, B; Vucinic, V, 2022) |
| "Consolidation radiotherapy for advanced Hodgkin lymphoma (AHL) is controversial." | ( Berthelsen, AK; Brown, PN; Loft, A; Maraldo, MV; Meidahl Petersen, P; Nielsen, K; Specht, L; Vogelius, IR, 2022) |
| "We report a rare case of a patient with Hodgkin lymphoma who developed grade 2 immune-related pneumonitis, requiring long-term low-dose glucocorticoid maintenance therapy, during which pneumonitis disappeared, and complete response was achieved." | ( Gao, Q; Li, T; Ma, B; Zhao, L; Zhou, Y, 2023) |
| "The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 μg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 μg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG)." | ( Aleman, BMP; Bisseling, TM; Carvalho, B; de Boer, JP; Gini, A; Janus, CPM; Lansdorp-Vogelaar, I; Lugtenburg, PJ; Meijer, GA; Moons, LMG; Petersen, EJ; Rigter, LS; Roesink, JM; Snaebjornsson, P; Spaander, MCW; van der Maazen, RWM; van Leerdam, ME; van Leeuwen, FE; Verbeek, WHM; Ykema, BLM, 2022) |
| "Patients with bulky stage I/II classic Hodgkin lymphoma (cHL) are typically treated with chemotherapy followed by radiation." | ( Abramson, J; Bartlett, NL; Blum, K; Bogart, J; Cheson, B; Dockter, T; Hsi, E; Kostakoglu, L; LaCasce, AS; Leonard, JP; Ruppert, AS; Schöder, H; Wagner-Johnston, N, 2023) |
| "In adults with advanced-stage Hodgkin's lymphoma, the CD30-directed antibody-drug conjugate brentuximab vedotin combined with multiagent chemotherapy has been shown to have greater efficacy, but also more toxic effects, than chemotherapy alone." | ( Castellino, SM; Charpentier, AM; Cho, S; Dave, H; Henderson, TO; Hodgson, D; Hoppe, BS; Horton, T; Keller, FG; Kelly, KM; McCarten, K; Parsons, SK; Pei, Q; Punnett, A; Wu, Y, 2022) |
| "Although classic Hodgkin lymphoma (cHL) is highly curable with current treatment paradigms, therapy fails in 10-25% of patients." | ( Cao, L; Ding, K; Fan, L; Li, J; Liu, H; Ma, J; Peng, H; Shi, W; Wang, H; Wu, W; Yang, H; Zhao, X; Zhu, H, 2023) |
| "Taken together, contemporary Hodgkin lymphoma-directed treatment approaches result in excellent outcomes for patients with newly diagnosed early-stage NLPHL and, thus, represent valid treatment options." | ( Baues, C; Borchmann, P; Bühnen, I; Dietlein, M; Eich, HT; Eichenauer, DA; Engert, A; Fuchs, M; Greil, R; Hartmann, S; Hertenstein, B; Just, M; Kaul, H; Kobe, C; Moccia, A; Topp, MS; von Tresckow, B; Zijlstra, JM, 2023) |
| "Management of classical Hodgkin lymphoma in older patients is challenging due to poor tolerance of the chemotherapy regimens used in younger patients." | ( Ferguson, G; Haynes, E; Hopkins, D; Leach, M; McKay, P; Murray, J; Osborne, W; Parsons, K; Quinn, D; Robertson, E; Wilson, MR, 2023) |
| "FRONTLINE THERAPY FOR CLASSICAL HODGKIN LYMPHOMA PATIENTS." | ( Casasnovas, O; Rossi, C, 2023) |
| "The treatment of older patients with Hodgkin lymphoma (HL) remains a challenge." | ( Baiocchi, O; Biasoli, I; Bonamin Sola, C; Boquimpani, C; Buccheri, V; Carvalho Palma, L; Castro, N; Chiattone, CS; Colaço Villarim, C; de Oliveira Marques, M; de Oliveira Paula E Silva, R; de Souza, C; Gaiolla, R; Goveia, L; Pagnano, K; Perobelli, L; Praxedes, M; Ribas, AC; Silveira, T; Soares, A; Solza, C; Souza Medina, S; Spector, N; Steffenello, G; Traina, F; Zattar Cecyn, K, 2023) |
| "The long-term survival of Hodgkin lymphoma (HL) patients treated according to the current standard of care is excellent." | ( Angelopoulou, MK; Gallamini, A; Liaskas, A; Panayiotidis, P; Pereyra, P; Vassilakopoulos, TP, 2023) |